Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receiving A Stable Dose Of Atorvastatin Or Treatment Naïve.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02055976

Enrollment

218

Registered

2014-02-05

Start date

2014-03-31

Completion date

2015-01-31

Last updated

2019-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

PF-04950615, Japan

Brief summary

The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C) lowering effect of Bococizumab (PF-04950615;RN316) administered subcutaneously at every two weeks (Q14D) in hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin, or who are naïve to a treatment by lipid lowering drug and whose LDL-C is not controlled.

Interventions

DRUGBococizumab (PF-04950615;RN316)

Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week

DRUGPlacebo

Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week

DRUGEzetimibe

Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population A). * Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not controlled (Population B).

Exclusion criteria

* Severe acute or chronic medical or psychiatric condition or laboratory abnormality. * Pregnant females; breastfeeding females; males and females of childbearing potential; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception. * Subjects who were administered or prior exposed to PF-04950615 and/or anti-body targeting PCSK9.

Design outcomes

Primary

Measure	Time frame	Description
Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	Baseline, Day 85	LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	Baseline, Day 113	LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Secondary

Measure	Time frame	Description
Total Cholesterol (TC)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Baseline, Day 85, 113	Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Baseline, Day 85, 113	Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Apolipoprotein B (ApoB)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Baseline, Day 85, 113	ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Baseline, Day 85, 113	ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Apolipoprotein A-I (ApoA-I)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Baseline, Day 85, 113	ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Baseline, Day 85, 113	ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Apolipoprotein A-II (ApoA-II)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Baseline, Day 85, 113	ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Baseline, Day 85, 113	ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Lipoprotein (a) (Lp[a])	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Baseline, Day 85, 113	Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Baseline, Day 85, 113	Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
High Density Lipoprotein- Cholesterol (HDL-C)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Triglyceride (TG)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Baseline, Day 85, 113	Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Baseline, Day 85, 113	Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	Baseline up to Day 113	LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection.
Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Baseline, Day 85, 113	Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Baseline, Day 85, 113	Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Baseline, Day 85, 113	Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.
Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Baseline, Day 85, 113	Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	Baseline up to Day 169	An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to Day 169 that were absent before treatment or that worsened relative to pretreatment state. Adverse events included treatment emergent injection site adverse events and any clinically significant abnormal laboratory value.
Number of Participants With Anti-Drug Antibody (ADA) Response	Baseline up to Day 169	Participants tested positive for ADA response on at least one post-baseline visit were reported. Participants with ADA titer level \>=6.23 for PF-04950615 were considered ADA positive.
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	Area under the plasma concentration time-curve from time zero to end of dosing interval (tau). This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	Area under the plasma concentration-time profile from time zero extrapolated to infinite time. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169	LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.
Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Terminal Elimination Half-Life (t1/2) of PF-04950615	Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141	Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =6.99 nanogram per milliliter \[ng/mL\]) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.
Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hr post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)	This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.
Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Baseline, Day 85, 113	LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Countries

Japan

Participant flow

Participants by arm

Arm	Count
Atorvastatin + PF-04950615 50 mg Participants with fasting lipoprotein cholesterol (LDL-C) level (greater than or equal to \[\>=\]100 milligram per deciliter \[mg/dL\]) received atorvastatin along with PF-04950615 50 milligram (mg) subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.	25
Atorvastatin + PF-04950615 100 mg Participants with fasting LDL-C level (\>=100 \[mg/dL\]) received atorvastatin along with PF-04950615 100 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.	24
Atorvastatin + PF-04950615 150 mg Participants with fasting LDL-C level (\>=100 \[mg/dL\]) received atorvastatin along with PF-04950615 150 mg subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.	24
Atorvastatin + PF-04950615 Placebo Participants with fasting LDL-C level (\>=100 \[mg/dL\]) received atorvastatin along with PF-04950615 placebo subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were on self-administered stable background atorvastatin therapy.	26
Atorvastatin + Ezetimibe 10 mg Participants with fasting LDL-C level (\>=100 \[mg/dL\]) received atorvastatin along with ezetimibe 10 mg tablet orally, once daily from Day 1 up to Day 112. Participants were on self-administered stable background atorvastatin therapy.	22
PF-04950615 50 mg Participants with fasting LDL-C level (\>=130 \[mg/dL\]) received PF-04950615 50 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.	25
PF-04950615 100 mg Participants with fasting LDL-C level (\>=130 \[mg/dL\]) received PF-04950615 100 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.	25
PF-04950615 150 mg Participants with fasting LDL-C level (\>=130 \[mg/dL\]) received PF-04950615 150 mg, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.	24
PF-04950615 Placebo Participants with fasting LDL-C level (\>=130 \[mg/dL\]) received PF-04950615 placebo, subcutaneous injection, once daily on Day 1, 15, 29, 43, 57, 71, 85 and 99. Participants were naive to a treatment by lipid lowering drug.	23
Total	218

Withdrawals & dropouts

Period	Reason	FG002	FG003	FG005	FG006
Overall Study	Adverse Event	0	0	1	1
Overall Study	Does not meet entrance criteria	0	0	0	1
Overall Study	Lost to Follow-up	0	1	0	0
Overall Study	Other	1	0	0	0

Baseline characteristics

Characteristic	Atorvastatin + PF-04950615 50 mg	Total	PF-04950615 Placebo	PF-04950615 150 mg	PF-04950615 100 mg	PF-04950615 50 mg	Atorvastatin + Ezetimibe 10 mg	Atorvastatin + PF-04950615 Placebo	Atorvastatin + PF-04950615 150 mg	Atorvastatin + PF-04950615 100 mg
Age, Customized 18-44 years	1 Participants	19 Participants	2 Participants	3 Participants	3 Participants	1 Participants	2 Participants	3 Participants	1 Participants	3 Participants
Age, Customized 45-64 years	18 Participants	134 Participants	12 Participants	20 Participants	14 Participants	16 Participants	14 Participants	14 Participants	16 Participants	10 Participants
Age, Customized Greater than or equal to (>=) 65 years	6 Participants	65 Participants	9 Participants	1 Participants	8 Participants	8 Participants	6 Participants	9 Participants	7 Participants	11 Participants
Age, Customized Less than (<) 18 years	0 Participants 8.9	0 Participants	0 Participants 11.7	0 Participants 8.1	0 Participants 10.6	0 Participants 8.4	0 Participants 10.7	0 Participants 11.2	0 Participants 8.6	0 Participants 12.2
Sex: Female, Male Female	8 Participants	100 Participants	10 Participants	9 Participants	15 Participants	13 Participants	10 Participants	13 Participants	12 Participants	10 Participants
Sex: Female, Male Male	17 Participants	118 Participants	13 Participants	15 Participants	10 Participants	12 Participants	12 Participants	13 Participants	12 Participants	14 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	10 / 25	12 / 24	12 / 24	10 / 26	2 / 22	11 / 25	11 / 25	11 / 24	9 / 23
serious Total, serious adverse events	1 / 25	0 / 24	0 / 24	1 / 26	0 / 22	0 / 25	1 / 25	0 / 24	0 / 23

Outcome results

Primary

Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113

LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Time frame: Baseline, Day 113

Population: FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, number of participants analyzed (N) signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-54.41 percent change	Standard Deviation 12.062
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-64.46 percent change	Standard Deviation 19.149
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-69.98 percent change	Standard Deviation 19.074
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-12.10 percent change	Standard Deviation 12.727
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-20.55 percent change	Standard Deviation 18.682
PF-04950615 50 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-44.94 percent change	Standard Deviation 19.641
PF-04950615 100 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-61.79 percent change	Standard Deviation 15.476
PF-04950615 150 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	-66.98 percent change	Standard Deviation 12.396
PF-04950615 Placebo	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113	0.39 percent change	Standard Deviation 16.246

Comparison: Adjusted mean difference and 2-sided 95% confidence interval were derived from the mixed-effect model for repeated measures (MMRM) model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-49.417, -35.168]Mixed Models Analysis

Comparison: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-63.603, -48.921]Mixed Models Analysis

Primary

Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85

Time frame: Baseline, Day 85

Population: Full analysis set (FAS) included all the participants who were randomized and administered at least 1 dose of study treatment.

Arm	Measure	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-55.65 percent change	Standard Deviation 15.748
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-68.25 percent change	Standard Deviation 18.769
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-74.00 percent change	Standard Deviation 13.848
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-5.91 percent change	Standard Deviation 14.323
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-18.56 percent change	Standard Deviation 15.968
PF-04950615 50 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-47.25 percent change	Standard Deviation 17.699
PF-04950615 100 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-62.24 percent change	Standard Deviation 16.097
PF-04950615 150 mg	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-65.89 percent change	Standard Deviation 10.779
PF-04950615 Placebo	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85	-1.21 percent change	Standard Deviation 14.815

Secondary

Apolipoprotein A-I (ApoA-I)

ApoA1 is a major protein that is a component of HDL cholesterol and helps in clearing cholesterol from the blood by removing cholesterol from organs and tissues to be destroyed by the liver. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Population: FAS included all the participants who were randomized and administered at least 1 dose of study treatment. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 43	144.52 mg/dL	Standard Deviation 12.842
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 22	143.20 mg/dL	Standard Deviation 15.554
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Baseline	137.02 mg/dL	Standard Deviation 13.235
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 57	138.40 mg/dL	Standard Deviation 14.919
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 127	144.08 mg/dL	Standard Deviation 18.63
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 106	145.92 mg/dL	Standard Deviation 18.773
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 50	145.80 mg/dL	Standard Deviation 15.042
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 113	139.21 mg/dL	Standard Deviation 15.731
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 15	141.56 mg/dL	Standard Deviation 13.811
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 5	140.72 mg/dL	Standard Deviation 14.644
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 36	143.48 mg/dL	Standard Deviation 15.273
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 71	145.50 mg/dL	Standard Deviation 16.192
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 29	144.32 mg/dL	Standard Deviation 15.118
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 155	143.52 mg/dL	Standard Deviation 17.564
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 85	138.04 mg/dL	Standard Deviation 14.968
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 169	142.96 mg/dL	Standard Deviation 20.387
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 141	145.46 mg/dL	Standard Deviation 19.006
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 99	147.40 mg/dL	Standard Deviation 18.771
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 8	140.44 mg/dL	Standard Deviation 14.972
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 36	149.88 mg/dL	Standard Deviation 17.957
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 50	151.25 mg/dL	Standard Deviation 19.157
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 43	153.88 mg/dL	Standard Deviation 18.262
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 155	148.83 mg/dL	Standard Deviation 20.267
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 5	146.65 mg/dL	Standard Deviation 16.773
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 141	151.21 mg/dL	Standard Deviation 18.99
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 8	147.46 mg/dL	Standard Deviation 16.707
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 127	148.75 mg/dL	Standard Deviation 17.738
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 113	149.17 mg/dL	Standard Deviation 18.719
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 15	153.00 mg/dL	Standard Deviation 16.325
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Baseline	142.60 mg/dL	Standard Deviation 16.507
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 106	154.96 mg/dL	Standard Deviation 19.282
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 99	154.54 mg/dL	Standard Deviation 17.84
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 22	152.88 mg/dL	Standard Deviation 18.473
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 85	148.17 mg/dL	Standard Deviation 16.818
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 29	155.79 mg/dL	Standard Deviation 19.598
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 169	151.54 mg/dL	Standard Deviation 19.01
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 57	149.46 mg/dL	Standard Deviation 19.509
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 71	152.92 mg/dL	Standard Deviation 21.086
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 22	151.78 mg/dL	Standard Deviation 20.576
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 169	150.96 mg/dL	Standard Deviation 19.025
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 127	150.04 mg/dL	Standard Deviation 23.145
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 85	144.04 mg/dL	Standard Deviation 15.933
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 155	149.52 mg/dL	Standard Deviation 21.848
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 141	154.17 mg/dL	Standard Deviation 22.321
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 71	150.43 mg/dL	Standard Deviation 21.002
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Baseline	140.31 mg/dL	Standard Deviation 18.813
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 50	149.13 mg/dL	Standard Deviation 19.008
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 29	151.78 mg/dL	Standard Deviation 22.913
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 15	150.46 mg/dL	Standard Deviation 20.479
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 43	150.33 mg/dL	Standard Deviation 22.584
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 106	150.23 mg/dL	Standard Deviation 18.341
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 5	144.48 mg/dL	Standard Deviation 19.943
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 113	144.13 mg/dL	Standard Deviation 18.587
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 99	150.86 mg/dL	Standard Deviation 21.108
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 57	145.83 mg/dL	Standard Deviation 18.93
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 8	146.88 mg/dL	Standard Deviation 19.2
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 36	150.13 mg/dL	Standard Deviation 21.102
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 8	147.00 mg/dL	Standard Deviation 21.527
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Baseline	145.65 mg/dL	Standard Deviation 21.908
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 5	146.08 mg/dL	Standard Deviation 21.505
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 15	147.04 mg/dL	Standard Deviation 22.704
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 22	145.31 mg/dL	Standard Deviation 21.481
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 29	144.28 mg/dL	Standard Deviation 20.633
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 36	143.46 mg/dL	Standard Deviation 20.609
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 43	142.42 mg/dL	Standard Deviation 21.495
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 50	143.46 mg/dL	Standard Deviation 20.397
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 57	137.62 mg/dL	Standard Deviation 18.206
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 71	142.62 mg/dL	Standard Deviation 19.15
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 85	136.00 mg/dL	Standard Deviation 20.229
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 99	147.48 mg/dL	Standard Deviation 20.799
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 106	143.12 mg/dL	Standard Deviation 17.822
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 113	137.72 mg/dL	Standard Deviation 21.454
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 127	145.60 mg/dL	Standard Deviation 22.763
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 141	148.52 mg/dL	Standard Deviation 23.261
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 155	147.60 mg/dL	Standard Deviation 23.076
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 169	154.88 mg/dL	Standard Deviation 23.938
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 141	144.45 mg/dL	Standard Deviation 16.721
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 99	145.91 mg/dL	Standard Deviation 16.798
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 50	141.95 mg/dL	Standard Deviation 15.807
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 43	144.64 mg/dL	Standard Deviation 16.105
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 36	145.91 mg/dL	Standard Deviation 18.652
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Baseline	145.34 mg/dL	Standard Deviation 16.171
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 113	145.00 mg/dL	Standard Deviation 14.69
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 169	153.64 mg/dL	Standard Deviation 21.367
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 85	144.23 mg/dL	Standard Deviation 14.498
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 57	142.18 mg/dL	Standard Deviation 15.445
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 22	146.41 mg/dL	Standard Deviation 17.012
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 5	144.68 mg/dL	Standard Deviation 16.193
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 106	144.64 mg/dL	Standard Deviation 15.413
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 8	145.57 mg/dL	Standard Deviation 16.351
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 155	147.09 mg/dL	Standard Deviation 16.446
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 29	146.23 mg/dL	Standard Deviation 17.221
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 127	144.27 mg/dL	Standard Deviation 14.701
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 15	148.50 mg/dL	Standard Deviation 18.918
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-I (ApoA-I)	Day 71	144.18 mg/dL	Standard Deviation 15.383
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 15	145.76 mg/dL	Standard Deviation 23.197
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 141	141.36 mg/dL	Standard Deviation 20.968
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 8	146.76 mg/dL	Standard Deviation 25.406
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 169	144.13 mg/dL	Standard Deviation 24.746
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 127	141.68 mg/dL	Standard Deviation 20.412
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 5	142.12 mg/dL	Standard Deviation 22.26
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 43	146.00 mg/dL	Standard Deviation 21.05
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 71	143.88 mg/dL	Standard Deviation 21.896
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 22	145.96 mg/dL	Standard Deviation 22.354
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Baseline	138.90 mg/dL	Standard Deviation 21.808
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 85	132.88 mg/dL	Standard Deviation 19.303
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 50	142.84 mg/dL	Standard Deviation 21.885
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 99	143.88 mg/dL	Standard Deviation 19.577
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 29	146.36 mg/dL	Standard Deviation 22.503
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 155	140.96 mg/dL	Standard Deviation 23.437
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 57	136.32 mg/dL	Standard Deviation 20.01
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 106	142.56 mg/dL	Standard Deviation 21.143
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 36	145.08 mg/dL	Standard Deviation 22.953
PF-04950615 50 mg	Apolipoprotein A-I (ApoA-I)	Day 113	138.40 mg/dL	Standard Deviation 19.581
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 99	151.29 mg/dL	Standard Deviation 21.612
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 169	151.70 mg/dL	Standard Deviation 21.699
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 8	145.79 mg/dL	Standard Deviation 19.26
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 15	150.08 mg/dL	Standard Deviation 20.762
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 57	145.96 mg/dL	Standard Deviation 22.029
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Baseline	145.38 mg/dL	Standard Deviation 19.26
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 43	152.32 mg/dL	Standard Deviation 21.059
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 5	145.12 mg/dL	Standard Deviation 18.485
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 127	148.48 mg/dL	Standard Deviation 18.012
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 106	149.26 mg/dL	Standard Deviation 19.909
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 113	149.09 mg/dL	Standard Deviation 18.033
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 50	152.52 mg/dL	Standard Deviation 19.739
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 155	148.09 mg/dL	Standard Deviation 21.037
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 85	145.13 mg/dL	Standard Deviation 17.168
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 36	153.33 mg/dL	Standard Deviation 19.417
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 29	150.04 mg/dL	Standard Deviation 21.763
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 22	150.08 mg/dL	Standard Deviation 19.019
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 71	151.88 mg/dL	Standard Deviation 17.523
PF-04950615 100 mg	Apolipoprotein A-I (ApoA-I)	Day 141	148.74 mg/dL	Standard Deviation 17.324
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 155	149.13 mg/dL	Standard Deviation 23.899
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 50	153.92 mg/dL	Standard Deviation 25.1
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 29	155.96 mg/dL	Standard Deviation 23.143
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 57	144.96 mg/dL	Standard Deviation 25.049
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 71	154.25 mg/dL	Standard Deviation 23.13
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 22	155.17 mg/dL	Standard Deviation 23.265
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 85	146.58 mg/dL	Standard Deviation 23.006
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 15	157.04 mg/dL	Standard Deviation 25.154
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 99	149.83 mg/dL	Standard Deviation 20.75
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 106	150.46 mg/dL	Standard Deviation 21.444
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 8	152.45 mg/dL	Standard Deviation 28.118
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 113	143.96 mg/dL	Standard Deviation 21.353
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 127	149.17 mg/dL	Standard Deviation 23.566
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 5	149.79 mg/dL	Standard Deviation 24.285
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 141	151.29 mg/dL	Standard Deviation 22.831
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Baseline	146.75 mg/dL	Standard Deviation 25.587
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 169	151.13 mg/dL	Standard Deviation 29.425
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 36	155.08 mg/dL	Standard Deviation 24.063
PF-04950615 150 mg	Apolipoprotein A-I (ApoA-I)	Day 43	155.75 mg/dL	Standard Deviation 32.193
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 141	149.13 mg/dL	Standard Deviation 19.328
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 106	141.17 mg/dL	Standard Deviation 15.497
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Baseline	150.13 mg/dL	Standard Deviation 16.834
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 43	149.04 mg/dL	Standard Deviation 16.932
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 155	148.83 mg/dL	Standard Deviation 18.077
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 169	154.36 mg/dL	Standard Deviation 19.742
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 99	144.65 mg/dL	Standard Deviation 19.812
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 36	149.30 mg/dL	Standard Deviation 18.639
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 50	145.70 mg/dL	Standard Deviation 14.348
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 15	151.00 mg/dL	Standard Deviation 19.214
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 85	136.30 mg/dL	Standard Deviation 16.753
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 71	146.17 mg/dL	Standard Deviation 14.981
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 22	151.65 mg/dL	Standard Deviation 17.185
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 57	138.87 mg/dL	Standard Deviation 16.491
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 127	144.48 mg/dL	Standard Deviation 15.237
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 5	150.09 mg/dL	Standard Deviation 17.989
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 113	140.04 mg/dL	Standard Deviation 16.767
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 8	150.48 mg/dL	Standard Deviation 16.782
PF-04950615 Placebo	Apolipoprotein A-I (ApoA-I)	Day 29	154.32 mg/dL	Standard Deviation 15.304

Secondary

Apolipoprotein A-II (ApoA-II)

ApoA-II is the second most abundant component of the HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 29	31.608 mg/dL	Standard Deviation 3.2712
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 50	31.772 mg/dL	Standard Deviation 3.9676
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 169	31.848 mg/dL	Standard Deviation 4.1778
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 71	32.600 mg/dL	Standard Deviation 4.3091
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 155	32.164 mg/dL	Standard Deviation 3.9476
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 99	32.868 mg/dL	Standard Deviation 4.2145
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 36	31.208 mg/dL	Standard Deviation 3.5747
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 8	30.224 mg/dL	Standard Deviation 2.8736
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 22	31.232 mg/dL	Standard Deviation 3.1787
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 85	30.484 mg/dL	Standard Deviation 4.5441
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Baseline	30.700 mg/dL	Standard Deviation 3.6817
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 106	31.908 mg/dL	Standard Deviation 4.1181
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 141	32.704 mg/dL	Standard Deviation 4.5005
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 113	30.442 mg/dL	Standard Deviation 4.1097
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 57	30.708 mg/dL	Standard Deviation 5.1285
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 5	30.884 mg/dL	Standard Deviation 3.6551
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 15	30.528 mg/dL	Standard Deviation 3.7034
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 127	32.068 mg/dL	Standard Deviation 3.9869
Atorvastatin + PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 43	31.600 mg/dL	Standard Deviation 3.8155
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Baseline	30.223 mg/dL	Standard Deviation 2.8992
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 169	32.033 mg/dL	Standard Deviation 3.8588
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 106	31.850 mg/dL	Standard Deviation 3.8284
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 36	30.838 mg/dL	Standard Deviation 3.392
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 29	32.279 mg/dL	Standard Deviation 4.1331
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 155	31.629 mg/dL	Standard Deviation 4.4463
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 141	32.325 mg/dL	Standard Deviation 4.2787
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 99	32.054 mg/dL	Standard Deviation 4.3729
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 50	31.117 mg/dL	Standard Deviation 3.5511
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 5	30.161 mg/dL	Standard Deviation 2.9004
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 85	30.296 mg/dL	Standard Deviation 4.2019
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 127	31.358 mg/dL	Standard Deviation 3.9263
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 113	30.313 mg/dL	Standard Deviation 4.1545
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 22	30.667 mg/dL	Standard Deviation 3.4561
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 71	31.554 mg/dL	Standard Deviation 4.3823
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 8	30.675 mg/dL	Standard Deviation 3.1077
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 57	30.271 mg/dL	Standard Deviation 4.039
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 43	31.908 mg/dL	Standard Deviation 4.2809
Atorvastatin + PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 15	31.129 mg/dL	Standard Deviation 2.9304
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 141	32.835 mg/dL	Standard Deviation 3.3582
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 85	29.974 mg/dL	Standard Deviation 3.3766
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 99	31.436 mg/dL	Standard Deviation 3.7821
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 155	31.878 mg/dL	Standard Deviation 3.3637
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 113	29.787 mg/dL	Standard Deviation 3.3975
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 5	30.443 mg/dL	Standard Deviation 3.4057
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 127	31.370 mg/dL	Standard Deviation 3.4158
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 8	30.738 mg/dL	Standard Deviation 2.9137
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 57	29.987 mg/dL	Standard Deviation 3.2086
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 15	31.304 mg/dL	Standard Deviation 3.0309
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 22	31.183 mg/dL	Standard Deviation 3.8763
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 29	31.035 mg/dL	Standard Deviation 3.7585
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 169	32.352 mg/dL	Standard Deviation 3.8903
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 36	30.622 mg/dL	Standard Deviation 3.387
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 106	31.073 mg/dL	Standard Deviation 3.3504
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 43	31.004 mg/dL	Standard Deviation 3.609
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 50	30.991 mg/dL	Standard Deviation 2.9264
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Baseline	30.471 mg/dL	Standard Deviation 2.8918
Atorvastatin + PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 71	31.148 mg/dL	Standard Deviation 2.8016
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 71	32.092 mg/dL	Standard Deviation 3.5748
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 5	31.608 mg/dL	Standard Deviation 3.6099
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 36	31.150 mg/dL	Standard Deviation 3.3011
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 15	32.062 mg/dL	Standard Deviation 3.2968
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 50	31.900 mg/dL	Standard Deviation 3.5621
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 22	31.846 mg/dL	Standard Deviation 3.0899
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 155	31.956 mg/dL	Standard Deviation 4.1374
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 99	32.500 mg/dL	Standard Deviation 4.3987
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 141	32.044 mg/dL	Standard Deviation 4.2146
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 43	31.685 mg/dL	Standard Deviation 3.6743
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 57	30.773 mg/dL	Standard Deviation 3.4292
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 169	33.120 mg/dL	Standard Deviation 4.2339
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 127	31.824 mg/dL	Standard Deviation 3.4922
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Baseline	31.515 mg/dL	Standard Deviation 3.8373
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 85	30.577 mg/dL	Standard Deviation 4.1019
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 29	32.096 mg/dL	Standard Deviation 3.6363
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 8	32.036 mg/dL	Standard Deviation 3.2261
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 113	30.388 mg/dL	Standard Deviation 3.3572
Atorvastatin + PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 106	31.724 mg/dL	Standard Deviation 3.5444
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 5	32.709 mg/dL	Standard Deviation 3.413
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 22	32.273 mg/dL	Standard Deviation 3.231
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 155	32.877 mg/dL	Standard Deviation 3.7858
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 36	32.091 mg/dL	Standard Deviation 4.0243
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 127	32.905 mg/dL	Standard Deviation 3.2614
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 15	33.136 mg/dL	Standard Deviation 3.6822
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 169	33.623 mg/dL	Standard Deviation 4.2722
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 43	32.636 mg/dL	Standard Deviation 3.1568
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 8	32.495 mg/dL	Standard Deviation 3.0372
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 113	32.559 mg/dL	Standard Deviation 3.0055
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 141	32.818 mg/dL	Standard Deviation 3.4188
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 71	33.127 mg/dL	Standard Deviation 3.3208
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 50	32.282 mg/dL	Standard Deviation 3.5327
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Baseline	32.189 mg/dL	Standard Deviation 3.2855
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 99	33.155 mg/dL	Standard Deviation 3.9087
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 85	33.095 mg/dL	Standard Deviation 3.4642
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 57	32.405 mg/dL	Standard Deviation 3.0798
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 106	32.432 mg/dL	Standard Deviation 3.6429
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein A-II (ApoA-II)	Day 29	32.395 mg/dL	Standard Deviation 3.1748
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 50	29.760 mg/dL	Standard Deviation 3.8077
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 127	30.904 mg/dL	Standard Deviation 3.1115
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 141	31.412 mg/dL	Standard Deviation 3.6261
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 5	30.088 mg/dL	Standard Deviation 3.4784
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 169	31.433 mg/dL	Standard Deviation 3.8678
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 8	30.760 mg/dL	Standard Deviation 3.3363
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 15	30.568 mg/dL	Standard Deviation 3.3308
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 22	30.620 mg/dL	Standard Deviation 3.3448
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 29	30.740 mg/dL	Standard Deviation 3.0899
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 57	28.548 mg/dL	Standard Deviation 3.871
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 36	29.768 mg/dL	Standard Deviation 3.2825
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 43	30.720 mg/dL	Standard Deviation 3.6371
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 155	31.061 mg/dL	Standard Deviation 3.8024
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 71	30.260 mg/dL	Standard Deviation 3.9125
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 85	29.036 mg/dL	Standard Deviation 3.6811
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 99	31.352 mg/dL	Standard Deviation 3.8161
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 106	30.520 mg/dL	Standard Deviation 3.9332
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Baseline	29.940 mg/dL	Standard Deviation 3.363
PF-04950615 50 mg	Apolipoprotein A-II (ApoA-II)	Day 113	29.300 mg/dL	Standard Deviation 3.3821
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 99	32.925 mg/dL	Standard Deviation 5.9562
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 50	32.704 mg/dL	Standard Deviation 3.8668
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Baseline	31.232 mg/dL	Standard Deviation 3.9681
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 43	32.408 mg/dL	Standard Deviation 4.03
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 57	31.454 mg/dL	Standard Deviation 4.3687
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 36	31.404 mg/dL	Standard Deviation 4.0581
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 29	31.100 mg/dL	Standard Deviation 3.6272
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 22	31.125 mg/dL	Standard Deviation 4.0921
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 141	33.287 mg/dL	Standard Deviation 3.0694
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 106	32.552 mg/dL	Standard Deviation 4.3131
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 113	32.361 mg/dL	Standard Deviation 4.148
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 15	31.516 mg/dL	Standard Deviation 3.9116
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 8	30.608 mg/dL	Standard Deviation 3.8492
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 5	30.972 mg/dL	Standard Deviation 4.2462
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 169	33.578 mg/dL	Standard Deviation 4.4671
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 85	31.957 mg/dL	Standard Deviation 4.8917
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 71	32.658 mg/dL	Standard Deviation 3.9677
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 155	32.891 mg/dL	Standard Deviation 4.087
PF-04950615 100 mg	Apolipoprotein A-II (ApoA-II)	Day 127	32.374 mg/dL	Standard Deviation 3.7973
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 85	30.533 mg/dL	Standard Deviation 4.0376
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Baseline	30.294 mg/dL	Standard Deviation 3.0541
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 5	30.558 mg/dL	Standard Deviation 3.0567
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 8	30.664 mg/dL	Standard Deviation 3.2942
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 15	31.275 mg/dL	Standard Deviation 3.4925
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 22	30.896 mg/dL	Standard Deviation 3.09
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 29	31.071 mg/dL	Standard Deviation 2.8639
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 36	30.975 mg/dL	Standard Deviation 3.3526
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 43	31.138 mg/dL	Standard Deviation 3.4691
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 50	31.083 mg/dL	Standard Deviation 3.8423
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 57	30.033 mg/dL	Standard Deviation 3.9031
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 71	31.804 mg/dL	Standard Deviation 3.5119
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 99	31.229 mg/dL	Standard Deviation 2.967
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 106	31.438 mg/dL	Standard Deviation 3.7623
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 113	30.239 mg/dL	Standard Deviation 3.2747
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 127	31.242 mg/dL	Standard Deviation 3.5215
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 141	32.029 mg/dL	Standard Deviation 3.497
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 155	31.867 mg/dL	Standard Deviation 3.6487
PF-04950615 150 mg	Apolipoprotein A-II (ApoA-II)	Day 169	32.070 mg/dL	Standard Deviation 3.9987
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 141	32.178 mg/dL	Standard Deviation 3.1213
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 106	30.865 mg/dL	Standard Deviation 3.7092
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 99	31.570 mg/dL	Standard Deviation 4.3204
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 85	29.657 mg/dL	Standard Deviation 3.6082
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 15	31.530 mg/dL	Standard Deviation 4.6451
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 71	31.317 mg/dL	Standard Deviation 4.0283
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 57	29.861 mg/dL	Standard Deviation 3.3007
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 50	30.830 mg/dL	Standard Deviation 3.7644
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 169	32.345 mg/dL	Standard Deviation 3.6908
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 155	31.439 mg/dL	Standard Deviation 3.405
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 43	31.922 mg/dL	Standard Deviation 3.8381
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 36	31.478 mg/dL	Standard Deviation 3.7066
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 29	31.882 mg/dL	Standard Deviation 3.696
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 22	32.200 mg/dL	Standard Deviation 3.694
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 8	31.635 mg/dL	Standard Deviation 3.6272
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 5	31.473 mg/dL	Standard Deviation 4.175
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 127	31.839 mg/dL	Standard Deviation 3.7256
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Day 113	30.126 mg/dL	Standard Deviation 3.5101
PF-04950615 Placebo	Apolipoprotein A-II (ApoA-II)	Baseline	31.354 mg/dL	Standard Deviation 3.9552

Secondary

Apolipoprotein B (ApoB)

ApoB is a major protein that makes up LDL cholesterol and is involved in transporting cholesterol and triglycerides to cells and tissues in the body. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 155	90.16 mg/dL	Standard Deviation 14.291
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 141	89.50 mg/dL	Standard Deviation 14.611
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 15	60.20 mg/dL	Standard Deviation 15.658
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 22	44.28 mg/dL	Standard Deviation 13.227
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 85	51.32 mg/dL	Standard Deviation 15.258
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 106	42.12 mg/dL	Standard Deviation 13.233
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 99	57.36 mg/dL	Standard Deviation 17.291
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 71	52.83 mg/dL	Standard Deviation 16.903
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Baseline	92.76 mg/dL	Standard Deviation 14.383
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 57	49.44 mg/dL	Standard Deviation 14.077
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 127	82.00 mg/dL	Standard Deviation 13.871
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 5	67.72 mg/dL	Standard Deviation 15.175
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 113	53.50 mg/dL	Standard Deviation 13.593
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 169	93.36 mg/dL	Standard Deviation 16.176
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 50	38.48 mg/dL	Standard Deviation 10.759
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 29	52.08 mg/dL	Standard Deviation 16.595
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 8	56.12 mg/dL	Standard Deviation 12.245
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 43	51.36 mg/dL	Standard Deviation 14.494
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 36	41.04 mg/dL	Standard Deviation 11.998
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 57	38.29 mg/dL	Standard Deviation 16.236
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 85	39.21 mg/dL	Standard Deviation 15.291
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 43	42.50 mg/dL	Standard Deviation 17.942
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 15	49.38 mg/dL	Standard Deviation 15.528
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 29	46.42 mg/dL	Standard Deviation 16.264
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 141	87.71 mg/dL	Standard Deviation 18.112
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 22	36.83 mg/dL	Standard Deviation 12.923
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 155	89.00 mg/dL	Standard Deviation 15.836
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 5	59.83 mg/dL	Standard Deviation 14.269
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 71	38.71 mg/dL	Standard Deviation 16.648
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 36	35.50 mg/dL	Standard Deviation 13.603
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 106	34.71 mg/dL	Standard Deviation 15.029
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 127	73.04 mg/dL	Standard Deviation 21.566
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 8	49.04 mg/dL	Standard Deviation 15.982
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 113	42.83 mg/dL	Standard Deviation 16.612
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 169	93.63 mg/dL	Standard Deviation 14.455
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 50	34.08 mg/dL	Standard Deviation 12.728
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Baseline	92.54 mg/dL	Standard Deviation 12.362
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 99	44.29 mg/dL	Standard Deviation 17.853
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 29	32.83 mg/dL	Standard Deviation 8.611
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 99	37.55 mg/dL	Standard Deviation 18.913
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 106	35.55 mg/dL	Standard Deviation 15.987
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Baseline	90.40 mg/dL	Standard Deviation 12.732
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 5	60.26 mg/dL	Standard Deviation 8.853
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 155	81.87 mg/dL	Standard Deviation 16.652
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 8	47.42 mg/dL	Standard Deviation 9.05
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 15	36.50 mg/dL	Standard Deviation 8.703
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 22	31.09 mg/dL	Standard Deviation 5.938
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 141	74.87 mg/dL	Standard Deviation 25.118
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 36	29.43 mg/dL	Standard Deviation 6.036
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 43	31.96 mg/dL	Standard Deviation 7.538
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 127	54.61 mg/dL	Standard Deviation 24.203
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 50	30.52 mg/dL	Standard Deviation 6.66
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 57	29.48 mg/dL	Standard Deviation 6.052
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 71	32.00 mg/dL	Standard Deviation 7.634
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 169	91.57 mg/dL	Standard Deviation 15.147
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 113	36.48 mg/dL	Standard Deviation 15.111
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 85	33.65 mg/dL	Standard Deviation 14.717
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 71	97.23 mg/dL	Standard Deviation 11.884
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 99	95.08 mg/dL	Standard Deviation 12.165
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 50	95.69 mg/dL	Standard Deviation 12.802
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 127	95.16 mg/dL	Standard Deviation 12.216
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Baseline	95.65 mg/dL	Standard Deviation 13.229
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 85	93.46 mg/dL	Standard Deviation 12.666
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 155	96.00 mg/dL	Standard Deviation 11.832
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 113	88.40 mg/dL	Standard Deviation 13.438
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 36	96.27 mg/dL	Standard Deviation 14.717
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 5	94.62 mg/dL	Standard Deviation 12.847
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 22	96.35 mg/dL	Standard Deviation 10.954
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 29	96.00 mg/dL	Standard Deviation 11.8
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 169	96.88 mg/dL	Standard Deviation 13.532
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 106	94.36 mg/dL	Standard Deviation 12.192
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 141	95.08 mg/dL	Standard Deviation 12.024
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 15	96.65 mg/dL	Standard Deviation 13.069
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 8	95.72 mg/dL	Standard Deviation 16.395
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 57	93.81 mg/dL	Standard Deviation 12.316
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 43	94.31 mg/dL	Standard Deviation 9.216
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 106	83.32 mg/dL	Standard Deviation 14.965
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 29	80.73 mg/dL	Standard Deviation 12.691
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 36	80.18 mg/dL	Standard Deviation 13.828
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 127	98.50 mg/dL	Standard Deviation 16.28
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 8	80.38 mg/dL	Standard Deviation 13.113
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 43	82.68 mg/dL	Standard Deviation 12.797
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 155	101.23 mg/dL	Standard Deviation 18.619
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 169	103.09 mg/dL	Standard Deviation 20.718
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 99	84.05 mg/dL	Standard Deviation 16.247
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 50	82.86 mg/dL	Standard Deviation 12.822
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 5	84.68 mg/dL	Standard Deviation 13.57
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Baseline	96.70 mg/dL	Standard Deviation 13.382
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 57	79.68 mg/dL	Standard Deviation 15.49
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 113	82.77 mg/dL	Standard Deviation 15.593
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 71	85.18 mg/dL	Standard Deviation 14.378
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 141	100.45 mg/dL	Standard Deviation 19.043
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 15	79.36 mg/dL	Standard Deviation 9.639
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 22	79.77 mg/dL	Standard Deviation 12.976
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB)	Day 85	86.77 mg/dL	Standard Deviation 16.934
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Baseline	106.54 mg/dL	Standard Deviation 15.8
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 113	69.08 mg/dL	Standard Deviation 17.007
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 71	69.96 mg/dL	Standard Deviation 19.673
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 127	97.20 mg/dL	Standard Deviation 20.827
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 36	62.40 mg/dL	Standard Deviation 19.885
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 8	82.52 mg/dL	Standard Deviation 19.402
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 141	108.96 mg/dL	Standard Deviation 21.279
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 29	69.32 mg/dL	Standard Deviation 20.613
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 99	72.56 mg/dL	Standard Deviation 18.063
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 155	111.39 mg/dL	Standard Deviation 17.758
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 169	112.46 mg/dL	Standard Deviation 16.005
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 50	62.28 mg/dL	Standard Deviation 19.932
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 5	88.40 mg/dL	Standard Deviation 18.777
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 15	82.24 mg/dL	Standard Deviation 21.127
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 106	66.72 mg/dL	Standard Deviation 17.111
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 43	67.24 mg/dL	Standard Deviation 19.959
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 85	68.68 mg/dL	Standard Deviation 17.409
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 22	68.76 mg/dL	Standard Deviation 20.949
PF-04950615 50 mg	Apolipoprotein B (ApoB)	Day 57	62.00 mg/dL	Standard Deviation 19.66
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Baseline	104.02 mg/dL	Standard Deviation 14.652
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 155	98.26 mg/dL	Standard Deviation 19.262
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 5	82.88 mg/dL	Standard Deviation 13.179
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 8	71.71 mg/dL	Standard Deviation 13.614
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 15	62.28 mg/dL	Standard Deviation 16.403
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 22	53.46 mg/dL	Standard Deviation 14.7
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 29	54.20 mg/dL	Standard Deviation 12.285
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 36	49.25 mg/dL	Standard Deviation 8.115
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 43	53.60 mg/dL	Standard Deviation 14.283
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 50	49.43 mg/dL	Standard Deviation 11.469
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 57	53.25 mg/dL	Standard Deviation 17.745
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 71	50.63 mg/dL	Standard Deviation 11.568
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 85	49.35 mg/dL	Standard Deviation 15.183
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 99	53.63 mg/dL	Standard Deviation 17.272
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 106	48.87 mg/dL	Standard Deviation 13.168
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 113	52.52 mg/dL	Standard Deviation 15.774
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 127	69.91 mg/dL	Standard Deviation 28.257
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 141	92.70 mg/dL	Standard Deviation 27.42
PF-04950615 100 mg	Apolipoprotein B (ApoB)	Day 169	105.91 mg/dL	Standard Deviation 17.661
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 29	50.25 mg/dL	Standard Deviation 11.752
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 22	50.54 mg/dL	Standard Deviation 15.3
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 50	47.58 mg/dL	Standard Deviation 14.443
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 15	58.08 mg/dL	Standard Deviation 12.265
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 57	45.79 mg/dL	Standard Deviation 12.322
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 169	95.74 mg/dL	Standard Deviation 21.764
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 141	77.67 mg/dL	Standard Deviation 25.466
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 43	48.50 mg/dL	Standard Deviation 14.301
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 8	70.27 mg/dL	Standard Deviation 16.237
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Baseline	101.88 mg/dL	Standard Deviation 11.494
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 5	78.00 mg/dL	Standard Deviation 14.025
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 36	46.92 mg/dL	Standard Deviation 14.191
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 113	45.87 mg/dL	Standard Deviation 11.53
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 155	86.04 mg/dL	Standard Deviation 23.451
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 127	62.75 mg/dL	Standard Deviation 19.525
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 99	45.88 mg/dL	Standard Deviation 11.211
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 71	47.79 mg/dL	Standard Deviation 12.112
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 106	47.00 mg/dL	Standard Deviation 12.332
PF-04950615 150 mg	Apolipoprotein B (ApoB)	Day 85	45.13 mg/dL	Standard Deviation 10.678
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 106	107.48 mg/dL	Standard Deviation 10.117
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 71	107.78 mg/dL	Standard Deviation 16.082
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 57	104.13 mg/dL	Standard Deviation 9.057
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 113	105.61 mg/dL	Standard Deviation 9.94
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 50	107.22 mg/dL	Standard Deviation 11.062
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 43	110.39 mg/dL	Standard Deviation 11.645
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 36	103.74 mg/dL	Standard Deviation 13.363
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 169	111.41 mg/dL	Standard Deviation 9.879
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 127	111.35 mg/dL	Standard Deviation 14.288
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 29	107.23 mg/dL	Standard Deviation 12.134
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 15	107.39 mg/dL	Standard Deviation 12.052
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 8	107.61 mg/dL	Standard Deviation 11.357
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 141	110.09 mg/dL	Standard Deviation 12.109
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 5	104.86 mg/dL	Standard Deviation 11.902
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Baseline	103.13 mg/dL	Standard Deviation 13.608
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 155	108.43 mg/dL	Standard Deviation 10.422
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 99	110.91 mg/dL	Standard Deviation 11.049
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 22	108.35 mg/dL	Standard Deviation 10.53
PF-04950615 Placebo	Apolipoprotein B (ApoB)	Day 85	102.09 mg/dL	Standard Deviation 12.387

Secondary

Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio

Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.4896 ratio	Standard Deviation 0.14794
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.2908 ratio	Standard Deviation 0.0845
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.6640 ratio	Standard Deviation 0.1435
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.3768 ratio	Standard Deviation 0.11546
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.3592 ratio	Standard Deviation 0.10723
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.3888 ratio	Standard Deviation 0.10343
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.3692 ratio	Standard Deviation 0.12402
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.6233 ratio	Standard Deviation 0.12107
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.4308 ratio	Standard Deviation 0.12426
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.3656 ratio	Standard Deviation 0.12076
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.2668 ratio	Standard Deviation 0.07669
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.3928 ratio	Standard Deviation 0.12458
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.3584 ratio	Standard Deviation 0.09715
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.2900 ratio	Standard Deviation 0.09278
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.6846 ratio	Standard Deviation 0.14145
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.6368 ratio	Standard Deviation 0.11957
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.5772 ratio	Standard Deviation 0.11473
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.3136 ratio	Standard Deviation 0.1061
Atorvastatin + PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.4044 ratio	Standard Deviation 0.09862
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.2463 ratio	Standard Deviation 0.09668
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.6321 ratio	Standard Deviation 0.14774
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.2421 ratio	Standard Deviation 0.10206
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.2592 ratio	Standard Deviation 0.11602
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.2908 ratio	Standard Deviation 0.11858
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.3058 ratio	Standard Deviation 0.12721
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.2267 ratio	Standard Deviation 0.10925
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.2696 ratio	Standard Deviation 0.11705
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.6125 ratio	Standard Deviation 0.15224
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.3363 ratio	Standard Deviation 0.11305
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.2642 ratio	Standard Deviation 0.13319
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.2800 ratio	Standard Deviation 0.12399
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.2313 ratio	Standard Deviation 0.10182
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.5938 ratio	Standard Deviation 0.15786
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.3300 ratio	Standard Deviation 0.12322
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.6606 ratio	Standard Deviation 0.13665
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.2904 ratio	Standard Deviation 0.12791
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.5029 ratio	Standard Deviation 0.17571
Atorvastatin + PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.4135 ratio	Standard Deviation 0.11264
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.2196 ratio	Standard Deviation 0.05943
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.2157 ratio	Standard Deviation 0.05281
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.2026 ratio	Standard Deviation 0.04081
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.4222 ratio	Standard Deviation 0.07116
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.6567 ratio	Standard Deviation 0.12772
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.5574 ratio	Standard Deviation 0.13288
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.3271 ratio	Standard Deviation 0.0676
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.5004 ratio	Standard Deviation 0.19354
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.2450 ratio	Standard Deviation 0.05649
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.3778 ratio	Standard Deviation 0.19064
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.2078 ratio	Standard Deviation 0.04572
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.2548 ratio	Standard Deviation 0.10845
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.6161 ratio	Standard Deviation 0.12493
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.2405 ratio	Standard Deviation 0.12187
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.1983 ratio	Standard Deviation 0.04376
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.2491 ratio	Standard Deviation 0.12432
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.2142 ratio	Standard Deviation 0.05012
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.2335 ratio	Standard Deviation 0.1017
Atorvastatin + PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.2048 ratio	Standard Deviation 0.04088
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.6873 ratio	Standard Deviation 0.15278
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.6773 ratio	Standard Deviation 0.13012
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.6584 ratio	Standard Deviation 0.1312
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.6938 ratio	Standard Deviation 0.12747
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.6692 ratio	Standard Deviation 0.13546
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.6712 ratio	Standard Deviation 0.13137
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.6580 ratio	Standard Deviation 0.13916
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.6687 ratio	Standard Deviation 0.12269
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.6958 ratio	Standard Deviation 0.1384
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.6788 ratio	Standard Deviation 0.12944
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.6660 ratio	Standard Deviation 0.14947
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.7023 ratio	Standard Deviation 0.13946
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.6804 ratio	Standard Deviation 0.13489
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.6664 ratio	Standard Deviation 0.13225
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.6716 ratio	Standard Deviation 0.12925
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.6776 ratio	Standard Deviation 0.12337
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.6556 ratio	Standard Deviation 0.14192
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.6424 ratio	Standard Deviation 0.14621
Atorvastatin + PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.6612 ratio	Standard Deviation 0.12682
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.5682 ratio	Standard Deviation 0.13297
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.6775 ratio	Standard Deviation 0.14076
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.5968 ratio	Standard Deviation 0.14211
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.5657 ratio	Standard Deviation 0.14552
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.5445 ratio	Standard Deviation 0.11164
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.5564 ratio	Standard Deviation 0.13347
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.5609 ratio	Standard Deviation 0.11924
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.5600 ratio	Standard Deviation 0.13551
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.5805 ratio	Standard Deviation 0.11978
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.5959 ratio	Standard Deviation 0.13893
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.5986 ratio	Standard Deviation 0.12434
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.6132 ratio	Standard Deviation 0.16069
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.5882 ratio	Standard Deviation 0.1593
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.5877 ratio	Standard Deviation 0.15253
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.5777 ratio	Standard Deviation 0.12976
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.6950 ratio	Standard Deviation 0.15732
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.7082 ratio	Standard Deviation 0.17595
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.6991 ratio	Standard Deviation 0.17124
Atorvastatin + Ezetimibe 10 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.6845 ratio	Standard Deviation 0.17986
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.5844 ratio	Standard Deviation 0.1841
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.5776 ratio	Standard Deviation 0.16885
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.8088 ratio	Standard Deviation 0.20105
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.8148 ratio	Standard Deviation 0.20102
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.4696 ratio	Standard Deviation 0.15115
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.4616 ratio	Standard Deviation 0.1522
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.4820 ratio	Standard Deviation 0.14437
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.7890 ratio	Standard Deviation 0.17841
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.4796 ratio	Standard Deviation 0.14386
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.7024 ratio	Standard Deviation 0.18033
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.4472 ratio	Standard Deviation 0.16198
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.6428 ratio	Standard Deviation 0.18885
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.7916 ratio	Standard Deviation 0.20262
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.5264 ratio	Standard Deviation 0.14405
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.4428 ratio	Standard Deviation 0.15255
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.4868 ratio	Standard Deviation 0.17148
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.4976 ratio	Standard Deviation 0.15592
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.5140 ratio	Standard Deviation 0.15398
PF-04950615 50 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.5164 ratio	Standard Deviation 0.15168
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.3557 ratio	Standard Deviation 0.1071
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.7178 ratio	Standard Deviation 0.18178
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.3283 ratio	Standard Deviation 0.08917
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.4216 ratio	Standard Deviation 0.11929
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.4730 ratio	Standard Deviation 0.18425
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.5017 ratio	Standard Deviation 0.1231
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.3804 ratio	Standard Deviation 0.18286
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.3358 ratio	Standard Deviation 0.07678
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.3250 ratio	Standard Deviation 0.06093
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.7324 ratio	Standard Deviation 0.16556
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.3650 ratio	Standard Deviation 0.15223
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.3632 ratio	Standard Deviation 0.14522
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.6839 ratio	Standard Deviation 0.19315
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.3720 ratio	Standard Deviation 0.11247
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.3322 ratio	Standard Deviation 0.0913
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.5792 ratio	Standard Deviation 0.11372
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.3629 ratio	Standard Deviation 0.10897
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.6352 ratio	Standard Deviation 0.20727
PF-04950615 100 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.3435 ratio	Standard Deviation 0.11007
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.4325 ratio	Standard Deviation 0.16469
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.3146 ratio	Standard Deviation 0.08086
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.3188 ratio	Standard Deviation 0.09124
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.7167 ratio	Standard Deviation 0.16058
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.3125 ratio	Standard Deviation 0.08125
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.3050 ratio	Standard Deviation 0.089
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.3075 ratio	Standard Deviation 0.0717
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.3254 ratio	Standard Deviation 0.07524
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.3142 ratio	Standard Deviation 0.0823
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.3283 ratio	Standard Deviation 0.0922
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.3235 ratio	Standard Deviation 0.08804
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.3763 ratio	Standard Deviation 0.08293
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.4718 ratio	Standard Deviation 0.139
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.5375 ratio	Standard Deviation 0.23022
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.5300 ratio	Standard Deviation 0.11967
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.6639 ratio	Standard Deviation 0.22661
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.6075 ratio	Standard Deviation 0.2412
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.3196 ratio	Standard Deviation 0.07765
PF-04950615 150 mg	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.3133 ratio	Standard Deviation 0.09234
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 141	0.7570 ratio	Standard Deviation 0.17219
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 5	0.7100 ratio	Standard Deviation 0.12642
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 50	0.7465 ratio	Standard Deviation 0.13878
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 22	0.7248 ratio	Standard Deviation 0.12409
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 106	0.7730 ratio	Standard Deviation 0.14455
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Baseline	0.6980 ratio	Standard Deviation 0.13867
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 29	0.7023 ratio	Standard Deviation 0.11439
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 99	0.7883 ratio	Standard Deviation 0.18622
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 43	0.7548 ratio	Standard Deviation 0.16351
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 155	0.7452 ratio	Standard Deviation 0.16318
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 36	0.7048 ratio	Standard Deviation 0.13413
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 85	0.7665 ratio	Standard Deviation 0.18376
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 71	0.7500 ratio	Standard Deviation 0.17328
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 8	0.7230 ratio	Standard Deviation 0.11227
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 127	0.7830 ratio	Standard Deviation 0.15893
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 15	0.7226 ratio	Standard Deviation 0.13404
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 113	0.7683 ratio	Standard Deviation 0.14272
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 169	0.7359 ratio	Standard Deviation 0.13397
PF-04950615 Placebo	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio	Day 57	0.7630 ratio	Standard Deviation 0.13394

Secondary

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615

Area under the plasma concentration time-curve from time zero to end of dosing interval (tau). This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Population: The pharmacokinetic (PK) parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose	32.98 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 57
Atorvastatin + PF-04950615 50 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Multiple dose	63.54 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 40
Atorvastatin + PF-04950615 100 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose	52.33 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 49
Atorvastatin + PF-04950615 100 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Multiple dose	92.46 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 127
Atorvastatin + PF-04950615 150 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose	77.11 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 43
Atorvastatin + PF-04950615 150 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Multiple dose	242.5 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 81
Atorvastatin + PF-04950615 Placebo	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose	32.97 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 42
Atorvastatin + PF-04950615 Placebo	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Multiple dose	63.74 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 57
Atorvastatin + Ezetimibe 10 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose	51.49 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 46
Atorvastatin + Ezetimibe 10 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Multiple dose	136.6 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 32
PF-04950615 50 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Single dose	82.05 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 45
PF-04950615 50 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615	Multiple dose	273.5 microgramday per milliliter(mcgday/mL)	Geometric Coefficient of Variation 100

Secondary

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615

Area under the plasma concentration-time profile from time zero extrapolated to infinite time. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Population: The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, number of participants analyzed (N) signifies participants evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	94.83 mcg*day/mL	Geometric Coefficient of Variation 46
Atorvastatin + PF-04950615 100 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	176.9 mcg*day/mL	Geometric Coefficient of Variation 144
Atorvastatin + PF-04950615 150 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	469.5 mcg*day/mL	Geometric Coefficient of Variation 90
Atorvastatin + PF-04950615 Placebo	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	111.7 mcg*day/mL	Geometric Coefficient of Variation 63
Atorvastatin + Ezetimibe 10 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	237.4 mcg*day/mL	Geometric Coefficient of Variation 41
PF-04950615 50 mg	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615	248.4 mcg*day/mL	Geometric Coefficient of Variation 76

Secondary

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615

Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Population: The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, N signifies participants evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	87.86 mcg*day/mL	Geometric Coefficient of Variation 49
Atorvastatin + PF-04950615 100 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	140.3 mcg*day/mL	Geometric Coefficient of Variation 145
Atorvastatin + PF-04950615 150 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	434.2 mcg*day/mL	Geometric Coefficient of Variation 91
Atorvastatin + PF-04950615 Placebo	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	96.32 mcg*day/mL	Geometric Coefficient of Variation 65
Atorvastatin + Ezetimibe 10 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	220.9 mcg*day/mL	Geometric Coefficient of Variation 39
PF-04950615 50 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	486.7 mcg*day/mL	Geometric Coefficient of Variation 143

Secondary

Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	1.02 mg/dL	Standard Deviation 9.479
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	2.52 mg/dL	Standard Deviation 9.226
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	5.56 mg/dL	Standard Deviation 10.575
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	6.56 mg/dL	Standard Deviation 12.31
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	3.72 mg/dL	Standard Deviation 11.977
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	3.63 mg/dL	Standard Deviation 11.155
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-9.65 mg/dL	Standard Deviation 9.495
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-7.86 mg/dL	Standard Deviation 13.052
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-1.11 mg/dL	Standard Deviation 11.118
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-0.34 mg/dL	Standard Deviation 10.783
PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-6.02 mg/dL	Standard Deviation 11.069
PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-0.50 mg/dL	Standard Deviation 9.512
PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	1.87 mg/dL	Standard Deviation 9.328
PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-2.09 mg/dL	Standard Deviation 12.04
PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-0.17 mg/dL	Standard Deviation 11.897
PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-3.54 mg/dL	Standard Deviation 8.982
PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-10.09 mg/dL	Standard Deviation 11.236
PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-13.83 mg/dL	Standard Deviation 10.602

Comparison: Day 85 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [3.646, 14.145]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [4.556, 16.573]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [6.993, 18.796]Mixed Models Analysis

Comparison: Day 113: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.00595% CI: [2.157, 15.13]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.01495% CI: [0.67, 10.864]Mixed Models Analysis

Secondary

Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-0.216 mg/dL	Standard Deviation 2.2274
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-0.073 mg/dL	Standard Deviation 2.0937
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	0.073 mg/dL	Standard Deviation 2.6605
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	0.090 mg/dL	Standard Deviation 2.3882
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-0.450 mg/dL	Standard Deviation 2.3906
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-0.637 mg/dL	Standard Deviation 2.2412
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-0.938 mg/dL	Standard Deviation 1.8339
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-1.104 mg/dL	Standard Deviation 4.0438
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	0.907 mg/dL	Standard Deviation 2.6785
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	0.370 mg/dL	Standard Deviation 2.2388
PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-0.640 mg/dL	Standard Deviation 2.0394
PF-04950615 50 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-0.904 mg/dL	Standard Deviation 2.3894
PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	0.759 mg/dL	Standard Deviation 2.2739
PF-04950615 100 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	0.354 mg/dL	Standard Deviation 3.3769
PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	0.240 mg/dL	Standard Deviation 3.1812
PF-04950615 150 mg	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	0.002 mg/dL	Standard Deviation 2.8256
PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-1.698 mg/dL	Standard Deviation 2.9589
PF-04950615 Placebo	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-1.228 mg/dL	Standard Deviation 3.4404

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.17695% CI: [-0.9066, 2.5177]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.01195% CI: [0.2899, 3.7242]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.02495% CI: [0.0184, 3.4049]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.13395% CI: [-0.6451, 2.313]Mixed Models Analysis

Secondary

Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.3078 ratio	Standard Deviation 0.13144
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.2998 ratio	Standard Deviation 0.12105
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.3910 ratio	Standard Deviation 0.15635
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.3698 ratio	Standard Deviation 0.16194
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.4211 ratio	Standard Deviation 0.16147
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.3998 ratio	Standard Deviation 0.15163
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	0.0337 ratio	Standard Deviation 0.09054
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.0170 ratio	Standard Deviation 0.10303
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.0643 ratio	Standard Deviation 0.11318
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.0998 ratio	Standard Deviation 0.09487
PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.2750 ratio	Standard Deviation 0.15604
PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.2626 ratio	Standard Deviation 0.16341
PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.3626 ratio	Standard Deviation 0.14553
PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.3748 ratio	Standard Deviation 0.17224
PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-0.4042 ratio	Standard Deviation 0.14894
PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-0.3965 ratio	Standard Deviation 0.15431
PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	0.0685 ratio	Standard Deviation 0.10818
PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	0.0702 ratio	Standard Deviation 0.09306

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-0.38399, -0.27916]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-0.49727, -0.39077]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-0.53671, -0.42956]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-0.3696, -0.24124]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-0.50466, -0.37821]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-0.52491, -0.3998]Mixed Models Analysis

Secondary

Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-41.44 mg/dL	Standard Deviation 16.385
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-39.56 mg/dL	Standard Deviation 12.011
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-53.33 mg/dL	Standard Deviation 19.097
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-49.71 mg/dL	Standard Deviation 18.699
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-56.43 mg/dL	Standard Deviation 17.65
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-53.61 mg/dL	Standard Deviation 16.526
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-2.19 mg/dL	Standard Deviation 10.703
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-7.70 mg/dL	Standard Deviation 12.436
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-9.93 mg/dL	Standard Deviation 14.35
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-13.93 mg/dL	Standard Deviation 12.65
PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-37.46 mg/dL	Standard Deviation 18.504
PF-04950615 50 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-37.86 mg/dL	Standard Deviation 18.125
PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-51.15 mg/dL	Standard Deviation 16.855
PF-04950615 100 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-54.33 mg/dL	Standard Deviation 21.08
PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-56.75 mg/dL	Standard Deviation 14.506
PF-04950615 150 mg	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-56.83 mg/dL	Standard Deviation 15.501
PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-1.04 mg/dL	Standard Deviation 13.02
PF-04950615 Placebo	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	2.48 mg/dL	Standard Deviation 11.107

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-61.543, -48.032]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-67.403, -53.694]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-43.999, -29.178]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-62.102, -47.265]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-63.845, -49.189]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-66.602, -52.614]Mixed Models Analysis

Secondary

Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113

HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	3.66 mg/dL	Standard Deviation 6.216
Atorvastatin + PF-04950615 50 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	3.90 mg/dL	Standard Deviation 6.437
Atorvastatin + PF-04950615 100 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	4.79 mg/dL	Standard Deviation 5.568
Atorvastatin + PF-04950615 100 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	6.29 mg/dL	Standard Deviation 7.003
Atorvastatin + PF-04950615 150 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	2.63 mg/dL	Standard Deviation 5.394
Atorvastatin + PF-04950615 150 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	2.33 mg/dL	Standard Deviation 8.053
Atorvastatin + PF-04950615 Placebo	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-4.58 mg/dL	Standard Deviation 4.573
Atorvastatin + PF-04950615 Placebo	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	-3.28 mg/dL	Standard Deviation 7.264
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	2.80 mg/dL	Standard Deviation 6.223
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	3.34 mg/dL	Standard Deviation 5.702
PF-04950615 50 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	0.70 mg/dL	Standard Deviation 6.489
PF-04950615 50 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-2.18 mg/dL	Standard Deviation 6.065
PF-04950615 100 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	1.37 mg/dL	Standard Deviation 7.799
PF-04950615 100 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	1.46 mg/dL	Standard Deviation 7.408
PF-04950615 150 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-0.02 mg/dL	Standard Deviation 7.575
PF-04950615 150 mg	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	-0.63 mg/dL	Standard Deviation 6.995
PF-04950615 Placebo	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-4.52 mg/dL	Standard Deviation 5.191
PF-04950615 Placebo	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	-4.70 mg/dL	Standard Deviation 5.045

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.01195% CI: [0.658, 7.943]Mixed Models Analysis

Secondary

Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113

Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-7.492 mg/dL	Standard Deviation 5.14
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-6.815 mg/dL	Standard Deviation 4.6182
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-10.119 mg/dL	Standard Deviation 5.4374
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-9.815 mg/dL	Standard Deviation 5.0568
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-10.239 mg/dL	Standard Deviation 8.2471
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-9.913 mg/dL	Standard Deviation 6.6763
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-2.746 mg/dL	Standard Deviation 3.1292
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-3.574 mg/dL	Standard Deviation 4.0251
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-1.859 mg/dL	Standard Deviation 3.0759
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-2.655 mg/dL	Standard Deviation 3.1725
PF-04950615 50 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-6.060 mg/dL	Standard Deviation 4.5477
PF-04950615 50 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-5.272 mg/dL	Standard Deviation 5.1528
PF-04950615 100 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-8.074 mg/dL	Standard Deviation 6.0886
PF-04950615 100 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-7.100 mg/dL	Standard Deviation 5.9402
PF-04950615 150 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-6.763 mg/dL	Standard Deviation 5.3474
PF-04950615 150 mg	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-7.098 mg/dL	Standard Deviation 4.5025
PF-04950615 Placebo	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-3.513 mg/dL	Standard Deviation 3.655
PF-04950615 Placebo	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-3.326 mg/dL	Standard Deviation 3.4975

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-6.263, -2.6118]Mixed Models Analysis

Secondary

Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113

LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-76.40 mg/dL	Standard Deviation 26.447
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-73.33 mg/dL	Standard Deviation 18.047
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-85.85 mg/dL	Standard Deviation 28.977
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-80.98 mg/dL	Standard Deviation 28.902
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-95.11 mg/dL	Standard Deviation 21.145
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-90.54 mg/dL	Standard Deviation 28.496
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-9.52 mg/dL	Standard Deviation 21.041
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-17.48 mg/dL	Standard Deviation 20.767
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-24.73 mg/dL	Standard Deviation 23.125
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-28.05 mg/dL	Standard Deviation 23.663
PF-04950615 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-74.78 mg/dL	Standard Deviation 34.97
PF-04950615 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-77.58 mg/dL	Standard Deviation 29.943
PF-04950615 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-97.63 mg/dL	Standard Deviation 25.545
PF-04950615 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-99.28 mg/dL	Standard Deviation 32.55
PF-04950615 150 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-105.19 mg/dL	Standard Deviation 19.833
PF-04950615 150 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-107.57 mg/dL	Standard Deviation 21.765
PF-04950615 Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 85	-3.91 mg/dL	Standard Deviation 23.632
PF-04950615 Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113	Change at Day 113	-1.91 mg/dL	Standard Deviation 20.147

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-110.743, -86.323]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-113.945, -90.424]Mixed Models Analysis

Secondary

Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113

Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-82.30 mg/dL	Standard Deviation 30.323
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-77.33 mg/dL	Standard Deviation 22.371
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-95.50 mg/dL	Standard Deviation 32.345
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-92.00 mg/dL	Standard Deviation 32.099
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-104.07 mg/dL	Standard Deviation 27.573
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-98.15 mg/dL	Standard Deviation 28.798
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-8.98 mg/dL	Standard Deviation 20.888
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-18.40 mg/dL	Standard Deviation 22.784
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-26.82 mg/dL	Standard Deviation 28.796
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-34.45 mg/dL	Standard Deviation 26.242
PF-04950615 50 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-76.92 mg/dL	Standard Deviation 35.588
PF-04950615 50 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-78.32 mg/dL	Standard Deviation 33.436
PF-04950615 100 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-99.26 mg/dL	Standard Deviation 27.347
PF-04950615 100 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-104.26 mg/dL	Standard Deviation 34.056
PF-04950615 150 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-110.00 mg/dL	Standard Deviation 24.274
PF-04950615 150 mg	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-111.33 mg/dL	Standard Deviation 24.646
PF-04950615 Placebo	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-6.00 mg/dL	Standard Deviation 24.009
PF-04950615 Placebo	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-0.52 mg/dL	Standard Deviation 20.267

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-86.975, -65.403]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-106.238, -84.172]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-117.239, -94.915]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-84.39, -58.077]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-113.768, -87.508]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-116.353, -90.42]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-121.519, -97.462]Mixed Models Analysis

Secondary

Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113

Total cholesterol is the sum of all the cholesterol within the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-73.44 mg/dL	Standard Deviation 21.242
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-78.64 mg/dL	Standard Deviation 28.525
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-90.71 mg/dL	Standard Deviation 31.705
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-85.71 mg/dL	Standard Deviation 30.263
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-95.83 mg/dL	Standard Deviation 27.765
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-101.43 mg/dL	Standard Deviation 25.436
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-13.56 mg/dL	Standard Deviation 22.346
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-21.68 mg/dL	Standard Deviation 23.686
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-24.02 mg/dL	Standard Deviation 26.166
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-31.11 mg/dL	Standard Deviation 24.992
PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-76.22 mg/dL	Standard Deviation 36.301
PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-80.50 mg/dL	Standard Deviation 31.851
PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-102.80 mg/dL	Standard Deviation 34.603
PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-97.89 mg/dL	Standard Deviation 29.274
PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-110.02 mg/dL	Standard Deviation 24.119
PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-111.96 mg/dL	Standard Deviation 24.871
PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-5.22 mg/dL	Standard Deviation 20.333
PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-10.52 mg/dL	Standard Deviation 26.111

Secondary

Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-1.6394 ratio	Standard Deviation 0.69058
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-1.5671 ratio	Standard Deviation 0.65875
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-1.9433 ratio	Standard Deviation 0.90358
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-1.9113 ratio	Standard Deviation 0.93385
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-1.8704 ratio	Standard Deviation 0.7363
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-1.9835 ratio	Standard Deviation 0.78766
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	0.0879 ratio	Standard Deviation 0.43755
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-0.1560 ratio	Standard Deviation 0.53286
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-0.6236 ratio	Standard Deviation 0.66072
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-0.7864 ratio	Standard Deviation 0.60966
PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-1.4204 ratio	Standard Deviation 0.91892
PF-04950615 50 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-1.4648 ratio	Standard Deviation 0.83864
PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-1.7563 ratio	Standard Deviation 0.74752
PF-04950615 100 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-1.8407 ratio	Standard Deviation 0.8526
PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-2.0469 ratio	Standard Deviation 0.9623
PF-04950615 150 mg	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-2.0461 ratio	Standard Deviation 0.92038
PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	0.2493 ratio	Standard Deviation 0.43772
PF-04950615 Placebo	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	0.1537 ratio	Standard Deviation 0.47755

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-1.96175, -1.43682]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-2.34622, -1.81223]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-2.50795, -1.96978]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-1.75689, -1.10872]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-2.33718, -1.69283]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-2.4323, -1.79489]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-2.48399, -1.92197]Mixed Models Analysis

Secondary

Change From Baseline in Triglyceride (TG) at Day 85 and Day 113

Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-28.68 mg/dL	Standard Deviation 41.898
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-20.02 mg/dL	Standard Deviation 41.197
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-27.96 mg/dL	Standard Deviation 49.754
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-45.33 mg/dL	Standard Deviation 53.285
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-29.52 mg/dL	Standard Deviation 40.669
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-30.13 mg/dL	Standard Deviation 48.592
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	2.58 mg/dL	Standard Deviation 35.796
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-0.58 mg/dL	Standard Deviation 63.896
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-10.14 mg/dL	Standard Deviation 43.129
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-23.45 mg/dL	Standard Deviation 51.443
PF-04950615 50 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-10.68 mg/dL	Standard Deviation 27.488
PF-04950615 50 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-3.76 mg/dL	Standard Deviation 37.502
PF-04950615 100 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	0.35 mg/dL	Standard Deviation 48.858
PF-04950615 100 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-15.87 mg/dL	Standard Deviation 48.341
PF-04950615 150 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-11.67 mg/dL	Standard Deviation 42.519
PF-04950615 150 mg	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-12.46 mg/dL	Standard Deviation 44.128
PF-04950615 Placebo	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-11.22 mg/dL	Standard Deviation 23.797
PF-04950615 Placebo	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	6.22 mg/dL	Standard Deviation 32.888

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-57.463, -14.472]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.00595% CI: [-51.123, -7.249]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-62.175, -17.845]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.61495% CI: [-18.502, 24.842]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.22195% CI: [-30.554, 13.427]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.30395% CI: [-27.376, 16.079]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.05295% CI: [-42.902, 4.032]Mixed Models Analysis

Secondary

Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113

VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Change from baseline = observed value minus baseline value.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-5.68 mg/dL	Standard Deviation 6.973
Atorvastatin + PF-04950615 50 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-4.29 mg/dL	Standard Deviation 8.538
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-6.17 mg/dL	Standard Deviation 7.171
Atorvastatin + PF-04950615 100 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-7.25 mg/dL	Standard Deviation 9.067
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-6.57 mg/dL	Standard Deviation 6.726
Atorvastatin + PF-04950615 150 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-5.35 mg/dL	Standard Deviation 6.619
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	1.15 mg/dL	Standard Deviation 4.841
Atorvastatin + PF-04950615 Placebo	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	0.34 mg/dL	Standard Deviation 10.957
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-2.70 mg/dL	Standard Deviation 7.069
Atorvastatin + Ezetimibe 10 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-3.98 mg/dL	Standard Deviation 8.873
PF-04950615 50 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-1.52 mg/dL	Standard Deviation 5.771
PF-04950615 50 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-0.76 mg/dL	Standard Deviation 5.114
PF-04950615 100 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-0.76 mg/dL	Standard Deviation 9.276
PF-04950615 100 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-2.63 mg/dL	Standard Deviation 9.497
PF-04950615 150 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-2.58 mg/dL	Standard Deviation 7.29
PF-04950615 150 mg	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-2.98 mg/dL	Standard Deviation 6.998
PF-04950615 Placebo	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-1.07 mg/dL	Standard Deviation 4.989
PF-04950615 Placebo	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	1.89 mg/dL	Standard Deviation 5.762

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-10.311, -4.614]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-9.61, -3.776]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-11.692, -5.817]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.48495% CI: [-3.596, 3.451]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.17395% CI: [-5.264, 1.862]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.13595% CI: [-5.452, 1.546]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.00495% CI: [-9.074, -1.469]Mixed Models Analysis

Secondary

High Density Lipoprotein- Cholesterol (HDL-C)

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	55.68 mg/dL	Standard Deviation 11.131
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	62.36 mg/dL	Standard Deviation 11.489
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	57.48 mg/dL	Standard Deviation 11.794
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	58.24 mg/dL	Standard Deviation 9.926
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	59.76 mg/dL	Standard Deviation 8.724
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	58.13 mg/dL	Standard Deviation 11.395
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	60.29 mg/dL	Standard Deviation 9.438
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	60.58 mg/dL	Standard Deviation 11.96
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	58.52 mg/dL	Standard Deviation 8.637
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	59.96 mg/dL	Standard Deviation 10.486
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	60.12 mg/dL	Standard Deviation 10.248
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	62.68 mg/dL	Standard Deviation 11.926
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	58.40 mg/dL	Standard Deviation 8.221
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	57.92 mg/dL	Standard Deviation 10.622
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	54.58 mg/dL	Standard Deviation 9.048
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	58.72 mg/dL	Standard Deviation 10.62
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	59.16 mg/dL	Standard Deviation 12.212
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	59.36 mg/dL	Standard Deviation 11.158
Atorvastatin + PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	56.48 mg/dL	Standard Deviation 11.266
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	60.08 mg/dL	Standard Deviation 12.176
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	59.04 mg/dL	Standard Deviation 12.726
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	60.50 mg/dL	Standard Deviation 13.112
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	62.96 mg/dL	Standard Deviation 14.0492
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	61.04 mg/dL	Standard Deviation 14.245
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	61.75 mg/dL	Standard Deviation 13.553
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	63.25 mg/dL	Standard Deviation 15.118
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	59.54 mg/dL	Standard Deviation 12.827
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	59.00 mg/dL	Standard Deviation 14.341
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	58.38 mg/dL	Standard Deviation 12.7
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	58.83 mg/dL	Standard Deviation 13.83
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	62.21 mg/dL	Standard Deviation 13.266
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	60.04 mg/dL	Standard Deviation 12.185
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	60.63 mg/dL	Standard Deviation 13.682
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	59.96 mg/dL	Standard Deviation 11.925
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	54.75 mg/dL	Standard Deviation 11.789
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	62.54 mg/dL	Standard Deviation 13.462
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	59.46 mg/dL	Standard Deviation 13.552
Atorvastatin + PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	57.04 mg/dL	Standard Deviation 12.532
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	63.83 mg/dL	Standard Deviation 15.948
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	64.83 mg/dL	Standard Deviation 16.854
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	60.35 mg/dL	Standard Deviation 13.231
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	58.43 mg/dL	Standard Deviation 13.48
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	57.00 mg/dL	Standard Deviation 12.858
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	61.96 mg/dL	Standard Deviation 14.455
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	60.33 mg/dL	Standard Deviation 13.017
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	64.26 mg/dL	Standard Deviation 14.53
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	62.79 mg/dL	Standard Deviation 15.562
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	62.78 mg/dL	Standard Deviation 14.013
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	64.52 mg/dL	Standard Deviation 14.585
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	59.39 mg/dL	Standard Deviation 12.565
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	62.48 mg/dL	Standard Deviation 14.441
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	64.41 mg/dL	Standard Deviation 13.355
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	62.39 mg/dL	Standard Deviation 14.151
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	62.32 mg/dL	Standard Deviation 14.496
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	62.29 mg/dL	Standard Deviation 15.415
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	59.70 mg/dL	Standard Deviation 11.315
Atorvastatin + PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	62.09 mg/dL	Standard Deviation 14.058
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	57.62 mg/dL	Standard Deviation 13.518
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	58.08 mg/dL	Standard Deviation 12.743
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	59.92 mg/dL	Standard Deviation 12.812
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	54.88 mg/dL	Standard Deviation 12.745
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	60.72 mg/dL	Standard Deviation 15.118
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	59.35 mg/dL	Standard Deviation 15.179
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	60.96 mg/dL	Standard Deviation 15.97
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	58.54 mg/dL	Standard Deviation 14.683
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	56.85 mg/dL	Standard Deviation 12.069
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	57.31 mg/dL	Standard Deviation 13.936
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	60.52 mg/dL	Standard Deviation 14.234
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	53.96 mg/dL	Standard Deviation 12.981
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	57.81 mg/dL	Standard Deviation 14.525
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	59.48 mg/dL	Standard Deviation 14.535
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	58.28 mg/dL	Standard Deviation 12.651
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	57.96 mg/dL	Standard Deviation 13.192
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	55.28 mg/dL	Standard Deviation 13.145
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	61.88 mg/dL	Standard Deviation 15.078
Atorvastatin + PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	58.19 mg/dL	Standard Deviation 14.403
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	57.45 mg/dL	Standard Deviation 10.804
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	56.98 mg/dL	Standard Deviation 9.607
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	57.00 mg/dL	Standard Deviation 9.866
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	58.67 mg/dL	Standard Deviation 10.136
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	60.23 mg/dL	Standard Deviation 12.208
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	60.05 mg/dL	Standard Deviation 10.017
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	59.00 mg/dL	Standard Deviation 9.587
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	58.23 mg/dL	Standard Deviation 10.314
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	58.82 mg/dL	Standard Deviation 10.45
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	58.55 mg/dL	Standard Deviation 10.835
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	58.00 mg/dL	Standard Deviation 9.798
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	59.77 mg/dL	Standard Deviation 10.438
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	60.36 mg/dL	Standard Deviation 10.472
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	59.45 mg/dL	Standard Deviation 10.117
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	60.32 mg/dL	Standard Deviation 10.049
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	57.82 mg/dL	Standard Deviation 9.272
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	59.09 mg/dL	Standard Deviation 10.766
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	59.45 mg/dL	Standard Deviation 9.179
Atorvastatin + Ezetimibe 10 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	60.50 mg/dL	Standard Deviation 11.827
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	59.60 mg/dL	Standard Deviation 15.729
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	60.24 mg/dL	Standard Deviation 16.048
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	60.29 mg/dL	Standard Deviation 16.206
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	59.04 mg/dL	Standard Deviation 16.425
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	59.36 mg/dL	Standard Deviation 14.95
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	57.16 mg/dL	Standard Deviation 12.589
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	60.84 mg/dL	Standard Deviation 16.222
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	57.22 mg/dL	Standard Deviation 14.146
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	60.08 mg/dL	Standard Deviation 15.231
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	58.56 mg/dL	Standard Deviation 13.818
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	59.40 mg/dL	Standard Deviation 14.955
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	57.20 mg/dL	Standard Deviation 15.785
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	59.40 mg/dL	Standard Deviation 16.081
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	55.04 mg/dL	Standard Deviation 13.421
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	59.76 mg/dL	Standard Deviation 14.521
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	60.92 mg/dL	Standard Deviation 16.253
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	59.16 mg/dL	Standard Deviation 13.539
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	57.92 mg/dL	Standard Deviation 14.617
PF-04950615 50 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	60.00 mg/dL	Standard Deviation 13.051
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	63.00 mg/dL	Standard Deviation 14.331
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	62.04 mg/dL	Standard Deviation 15.155
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	64.91 mg/dL	Standard Deviation 13.651
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	62.32 mg/dL	Standard Deviation 15.513
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	63.61 mg/dL	Standard Deviation 16.16
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	61.33 mg/dL	Standard Deviation 14.23
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	61.92 mg/dL	Standard Deviation 14.374
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	63.92 mg/dL	Standard Deviation 14.185
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	65.25 mg/dL	Standard Deviation 14.411
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	60.40 mg/dL	Standard Deviation 13.228
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	64.54 mg/dL	Standard Deviation 15.453
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	63.64 mg/dL	Standard Deviation 15.435
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	63.00 mg/dL	Standard Deviation 15.021
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	62.52 mg/dL	Standard Deviation 15.196
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	64.39 mg/dL	Standard Deviation 15.718
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	60.32 mg/dL	Standard Deviation 13.643
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	63.92 mg/dL	Standard Deviation 13.529
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	63.26 mg/dL	Standard Deviation 14.229
PF-04950615 100 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	63.09 mg/dL	Standard Deviation 13.211
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	63.88 mg/dL	Standard Deviation 19.161
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	66.29 mg/dL	Standard Deviation 20.354
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	65.17 mg/dL	Standard Deviation 18.846
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	62.02 mg/dL	Standard Deviation 21.455
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	62.00 mg/dL	Standard Deviation 17.619
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	65.21 mg/dL	Standard Deviation 19.489
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	64.63 mg/dL	Standard Deviation 18.946
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	67.96 mg/dL	Standard Deviation 20.412
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	65.17 mg/dL	Standard Deviation 18.897
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	65.38 mg/dL	Standard Deviation 17.358
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	61.83 mg/dL	Standard Deviation 18.218
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	66.58 mg/dL	Standard Deviation 22.085
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	64.00 mg/dL	Standard Deviation 23.42
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	64.00 mg/dL	Standard Deviation 20.167
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	62.08 mg/dL	Standard Deviation 21.354
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	65.00 mg/dL	Standard Deviation 24.355
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	63.67 mg/dL	Standard Deviation 20.55
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	62.63 mg/dL	Standard Deviation 20.549
PF-04950615 150 mg	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	65.21 mg/dL	Standard Deviation 19.669
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 141	62.39 mg/dL	Standard Deviation 14.138
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 5	59.73 mg/dL	Standard Deviation 11.344
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 50	59.39 mg/dL	Standard Deviation 10.586
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 22	61.48 mg/dL	Standard Deviation 11.233
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 106	58.30 mg/dL	Standard Deviation 11.703
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Baseline	60.87 mg/dL	Standard Deviation 10.606
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 29	64.14 mg/dL	Standard Deviation 9.896
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 99	59.30 mg/dL	Standard Deviation 12.43
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 43	59.74 mg/dL	Standard Deviation 10.558
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 155	61.87 mg/dL	Standard Deviation 13.602
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 36	59.91 mg/dL	Standard Deviation 10.833
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 85	56.35 mg/dL	Standard Deviation 10.075
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 71	57.78 mg/dL	Standard Deviation 9.662
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 8	60.57 mg/dL	Standard Deviation 11.289
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 127	58.00 mg/dL	Standard Deviation 10.838
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 15	60.30 mg/dL	Standard Deviation 11.117
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 113	56.17 mg/dL	Standard Deviation 10.421
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 169	65.05 mg/dL	Standard Deviation 13.584
PF-04950615 Placebo	High Density Lipoprotein- Cholesterol (HDL-C)	Day 57	56.61 mg/dL	Standard Deviation 10.782

Secondary

Lipoprotein (a) (Lp[a])

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 8	14.892 mg/dL	Standard Deviation 13.2944
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 85	10.960 mg/dL	Standard Deviation 11.6806
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Baseline	18.452 mg/dL	Standard Deviation 13.1792
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 155	17.264 mg/dL	Standard Deviation 15.4506
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 15	14.208 mg/dL	Standard Deviation 12.928
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 106	10.756 mg/dL	Standard Deviation 11.7377
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 57	10.708 mg/dL	Standard Deviation 10.3883
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 113	12.108 mg/dL	Standard Deviation 12.3479
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 43	11.648 mg/dL	Standard Deviation 12.2798
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 127	15.476 mg/dL	Standard Deviation 14.6308
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 36	11.152 mg/dL	Standard Deviation 11.9088
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 71	11.358 mg/dL	Standard Deviation 12.3793
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 99	12.232 mg/dL	Standard Deviation 12.5326
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 141	16.842 mg/dL	Standard Deviation 15.6809
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 29	12.832 mg/dL	Standard Deviation 12.3874
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 50	10.344 mg/dL	Standard Deviation 11.3684
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 5	16.224 mg/dL	Standard Deviation 13.4935
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 169	17.824 mg/dL	Standard Deviation 15.1879
Atorvastatin + PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 22	12.628 mg/dL	Standard Deviation 12.4393
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 5	18.348 mg/dL	Standard Deviation 17.7316
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 85	10.879 mg/dL	Standard Deviation 14.1289
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 99	11.837 mg/dL	Standard Deviation 15.6082
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 169	17.404 mg/dL	Standard Deviation 18.0405
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 8	15.333 mg/dL	Standard Deviation 18.3499
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 155	17.483 mg/dL	Standard Deviation 19.9385
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 15	14.129 mg/dL	Standard Deviation 17.8567
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 50	11.675 mg/dL	Standard Deviation 14.8818
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 22	12.446 mg/dL	Standard Deviation 16.1397
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 141	17.329 mg/dL	Standard Deviation 18.9837
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 29	13.379 mg/dL	Standard Deviation 16.2405
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Baseline	20.998 mg/dL	Standard Deviation 17.2111
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 36	12.833 mg/dL	Standard Deviation 16.0418
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 127	15.112 mg/dL	Standard Deviation 16.5781
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 43	12.525 mg/dL	Standard Deviation 16.136
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 113	11.183 mg/dL	Standard Deviation 14.5312
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 57	10.871 mg/dL	Standard Deviation 13.5224
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 106	11.079 mg/dL	Standard Deviation 14.259
Atorvastatin + PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 71	11.354 mg/dL	Standard Deviation 14.0492
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 106	9.123 mg/dL	Standard Deviation 14.1064
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 36	10.409 mg/dL	Standard Deviation 12.7145
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 8	14.167 mg/dL	Standard Deviation 15.5022
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 169	16.635 mg/dL	Standard Deviation 17.8211
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 50	9.039 mg/dL	Standard Deviation 12.025
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 127	11.961 mg/dL	Standard Deviation 15.6073
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 15	11.392 mg/dL	Standard Deviation 14.1251
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 5	16.204 mg/dL	Standard Deviation 16.6072
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 113	9.565 mg/dL	Standard Deviation 14.0691
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 43	9.633 mg/dL	Standard Deviation 12.436
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 57	8.578 mg/dL	Standard Deviation 11.2275
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 29	10.552 mg/dL	Standard Deviation 12.7986
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Baseline	18.840 mg/dL	Standard Deviation 16.7289
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 71	9.009 mg/dL	Standard Deviation 11.7733
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 85	9.239 mg/dL	Standard Deviation 11.1448
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 22	10.765 mg/dL	Standard Deviation 13.3504
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 155	16.052 mg/dL	Standard Deviation 16.9174
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 141	14.422 mg/dL	Standard Deviation 17.362
Atorvastatin + PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 99	8.855 mg/dL	Standard Deviation 13.9399
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 106	15.396 mg/dL	Standard Deviation 12.8944
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 57	15.892 mg/dL	Standard Deviation 14.099
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 22	18.785 mg/dL	Standard Deviation 16.0604
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 141	15.828 mg/dL	Standard Deviation 13.7114
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 99	15.764 mg/dL	Standard Deviation 14.4527
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 29	18.304 mg/dL	Standard Deviation 15.605
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 5	18.523 mg/dL	Standard Deviation 15.2512
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 127	15.500 mg/dL	Standard Deviation 13.0255
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 36	17.046 mg/dL	Standard Deviation 14.4893
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 71	16.542 mg/dL	Standard Deviation 13.5029
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 43	16.912 mg/dL	Standard Deviation 14.1356
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 169	15.384 mg/dL	Standard Deviation 13.715
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 113	14.492 mg/dL	Standard Deviation 12.906
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 50	16.835 mg/dL	Standard Deviation 14.2068
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 85	16.519 mg/dL	Standard Deviation 14.5691
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Baseline	19.265 mg/dL	Standard Deviation 14.3646
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 155	16.004 mg/dL	Standard Deviation 13.7418
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 15	19.258 mg/dL	Standard Deviation 16.0484
Atorvastatin + PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 8	19.184 mg/dL	Standard Deviation 14.7461
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 50	17.314 mg/dL	Standard Deviation 19.6439
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 36	18.050 mg/dL	Standard Deviation 19.5448
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 71	16.991 mg/dL	Standard Deviation 20.0151
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Baseline	19.468 mg/dL	Standard Deviation 18.4181
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 106	16.682 mg/dL	Standard Deviation 18.8434
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 141	17.236 mg/dL	Standard Deviation 18.8525
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 57	17.573 mg/dL	Standard Deviation 21.9401
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 127	16.618 mg/dL	Standard Deviation 19.1791
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 155	17.382 mg/dL	Standard Deviation 19.8297
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 8	17.243 mg/dL	Standard Deviation 15.7353
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 99	16.868 mg/dL	Standard Deviation 19.6709
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 29	17.873 mg/dL	Standard Deviation 18.0678
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 43	17.214 mg/dL	Standard Deviation 18.6825
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 5	20.450 mg/dL	Standard Deviation 18.8904
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 113	16.814 mg/dL	Standard Deviation 17.8976
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 22	17.800 mg/dL	Standard Deviation 18.6499
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 85	17.609 mg/dL	Standard Deviation 19.7001
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 169	17.059 mg/dL	Standard Deviation 20.8409
Atorvastatin + Ezetimibe 10 mg	Lipoprotein (a) (Lp[a])	Day 15	18.982 mg/dL	Standard Deviation 20.4348
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 141	10.100 mg/dL	Standard Deviation 10.9325
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Baseline	14.080 mg/dL	Standard Deviation 11.9369
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 5	12.464 mg/dL	Standard Deviation 10.5751
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 8	12.000 mg/dL	Standard Deviation 11.8358
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 15	10.140 mg/dL	Standard Deviation 10.0017
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 22	10.936 mg/dL	Standard Deviation 10.192
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 29	10.424 mg/dL	Standard Deviation 10.6085
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 36	9.484 mg/dL	Standard Deviation 10.6692
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 43	9.380 mg/dL	Standard Deviation 9.6416
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 50	10.040 mg/dL	Standard Deviation 10.4835
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 57	9.392 mg/dL	Standard Deviation 10.2457
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 71	9.248 mg/dL	Standard Deviation 11.4972
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 85	8.808 mg/dL	Standard Deviation 10.3417
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 99	7.940 mg/dL	Standard Deviation 9.6343
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 106	8.608 mg/dL	Standard Deviation 9.5662
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 113	8.020 mg/dL	Standard Deviation 9.0412
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 127	9.864 mg/dL	Standard Deviation 10.2016
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 155	10.204 mg/dL	Standard Deviation 11.272
PF-04950615 50 mg	Lipoprotein (a) (Lp[a])	Day 169	11.271 mg/dL	Standard Deviation 11.4561
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 57	9.487 mg/dL	Standard Deviation 8.2801
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 99	8.537 mg/dL	Standard Deviation 7.6094
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 22	11.583 mg/dL	Standard Deviation 11.3914
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 155	13.465 mg/dL	Standard Deviation 10.8114
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 36	10.329 mg/dL	Standard Deviation 9.7943
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 29	10.888 mg/dL	Standard Deviation 9.845
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Baseline	15.458 mg/dL	Standard Deviation 12.6296
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 169	13.613 mg/dL	Standard Deviation 11.5074
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 127	10.543 mg/dL	Standard Deviation 9.2205
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 106	8.296 mg/dL	Standard Deviation 7.341
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 71	9.529 mg/dL	Standard Deviation 8.6412
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 8	12.617 mg/dL	Standard Deviation 10.4189
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 5	14.580 mg/dL	Standard Deviation 12.2541
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 50	10.191 mg/dL	Standard Deviation 9.263
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 15	12.548 mg/dL	Standard Deviation 10.986
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 85	9.261 mg/dL	Standard Deviation 7.6804
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 43	9.944 mg/dL	Standard Deviation 9.7431
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 141	11.996 mg/dL	Standard Deviation 10.0494
PF-04950615 100 mg	Lipoprotein (a) (Lp[a])	Day 113	8.287 mg/dL	Standard Deviation 7.6439
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 15	9.996 mg/dL	Standard Deviation 8.1113
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 99	6.792 mg/dL	Standard Deviation 5.6212
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 57	6.858 mg/dL	Standard Deviation 6.2894
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 106	6.858 mg/dL	Standard Deviation 6.1058
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 50	7.621 mg/dL	Standard Deviation 6.5659
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 43	8.821 mg/dL	Standard Deviation 7.6426
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 113	6.787 mg/dL	Standard Deviation 5.8743
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 36	8.067 mg/dL	Standard Deviation 6.7186
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 29	9.312 mg/dL	Standard Deviation 7.3675
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 127	7.642 mg/dL	Standard Deviation 6.9977
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 22	8.800 mg/dL	Standard Deviation 7.1835
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 141	8.442 mg/dL	Standard Deviation 6.7945
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 8	12.768 mg/dL	Standard Deviation 8.9168
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 169	10.626 mg/dL	Standard Deviation 8.0902
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 155	9.600 mg/dL	Standard Deviation 7.5028
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 5	11.783 mg/dL	Standard Deviation 9.3506
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 85	6.637 mg/dL	Standard Deviation 5.6695
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Day 71	6.979 mg/dL	Standard Deviation 6.5414
PF-04950615 150 mg	Lipoprotein (a) (Lp[a])	Baseline	13.400 mg/dL	Standard Deviation 9.0719
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 141	13.139 mg/dL	Standard Deviation 9.2951
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 43	15.961 mg/dL	Standard Deviation 10.389
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 8	16.443 mg/dL	Standard Deviation 12.1793
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Baseline	16.239 mg/dL	Standard Deviation 10.1883
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 106	12.800 mg/dL	Standard Deviation 8.9601
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 5	15.859 mg/dL	Standard Deviation 10.9932
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 85	12.726 mg/dL	Standard Deviation 8.9598
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 50	15.078 mg/dL	Standard Deviation 9.7608
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 71	13.500 mg/dL	Standard Deviation 9.4333
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 155	13.183 mg/dL	Standard Deviation 9.171
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 127	13.596 mg/dL	Standard Deviation 9.334
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 29	17.423 mg/dL	Standard Deviation 11.1746
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 22	16.026 mg/dL	Standard Deviation 11.008
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 99	13.691 mg/dL	Standard Deviation 9.5937
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 36	15.843 mg/dL	Standard Deviation 10.805
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 15	16.443 mg/dL	Standard Deviation 11.4594
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 113	12.913 mg/dL	Standard Deviation 9.7212
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 169	14.741 mg/dL	Standard Deviation 10.3647
PF-04950615 Placebo	Lipoprotein (a) (Lp[a])	Day 57	14.313 mg/dL	Standard Deviation 9.393

Secondary

Low Density Lipoprotein-Cholesterol (LDL-C)

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	86.72 mg/dL	Standard Deviation 24.917
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	45.16 mg/dL	Standard Deviation 20.874
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	131.28 mg/dL	Standard Deviation 25.988
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	58.96 mg/dL	Standard Deviation 19.65
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	58.24 mg/dL	Standard Deviation 21.357
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	62.17 mg/dL	Standard Deviation 20.417
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	61.50 mg/dL	Standard Deviation 22.683
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	126.13 mg/dL	Standard Deviation 26.555
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	73.76 mg/dL	Standard Deviation 18.807
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	61.56 mg/dL	Standard Deviation 24.316
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	39.76 mg/dL	Standard Deviation 16.042
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	66.48 mg/dL	Standard Deviation 23.208
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	56.88 mg/dL	Standard Deviation 18.306
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	44.40 mg/dL	Standard Deviation 19.967
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	135.36 mg/dL	Standard Deviation 23.652
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	126.52 mg/dL	Standard Deviation 23.631
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	108.16 mg/dL	Standard Deviation 21.893
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	49.08 mg/dL	Standard Deviation 19.577
Atorvastatin + PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	70.36 mg/dL	Standard Deviation 18.932
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	37.58 mg/dL	Standard Deviation 20.011
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	123.42 mg/dL	Standard Deviation 25.782
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	35.13 mg/dL	Standard Deviation 17.306
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	36.29 mg/dL	Standard Deviation 18.196
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	42.88 mg/dL	Standard Deviation 19.427
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	48.29 mg/dL	Standard Deviation 21.814
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	32.13 mg/dL	Standard Deviation 18.059
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	38.00 mg/dL	Standard Deviation 19.077
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	113.75 mg/dL	Standard Deviation 19.236
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	55.38 mg/dL	Standard Deviation 28.309
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	37.21 mg/dL	Standard Deviation 18.352
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	39.63 mg/dL	Standard Deviation 20.342
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	32.33 mg/dL	Standard Deviation 16.578
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	111.38 mg/dL	Standard Deviation 24.588
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	51.96 mg/dL	Standard Deviation 23.921
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	123.85 mg/dL	Standard Deviation 20.585
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	41.96 mg/dL	Standard Deviation 18.995
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	86.71 mg/dL	Standard Deviation 27.414
Atorvastatin + PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	71.83 mg/dL	Standard Deviation 26.02
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	34.26 mg/dL	Standard Deviation 13.965
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	33.13 mg/dL	Standard Deviation 13.384
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	29.61 mg/dL	Standard Deviation 11.053
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	76.04 mg/dL	Standard Deviation 17.111
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	129.19 mg/dL	Standard Deviation 17.769
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	110.57 mg/dL	Standard Deviation 26.678
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	57.71 mg/dL	Standard Deviation 16.433
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	95.30 mg/dL	Standard Deviation 37.497
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	39.00 mg/dL	Standard Deviation 16.395
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	61.87 mg/dL	Standard Deviation 33.267
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	31.00 mg/dL	Standard Deviation 11.176
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	38.48 mg/dL	Standard Deviation 24.346
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	124.04 mg/dL	Standard Deviation 24.453
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	37.36 mg/dL	Standard Deviation 24.849
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	29.52 mg/dL	Standard Deviation 11.233
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	38.09 mg/dL	Standard Deviation 25.183
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	31.83 mg/dL	Standard Deviation 11.75
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	33.91 mg/dL	Standard Deviation 19.4
Atorvastatin + PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	29.96 mg/dL	Standard Deviation 11.4
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	128.50 mg/dL	Standard Deviation 23.93
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	133.27 mg/dL	Standard Deviation 19.359
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	125.80 mg/dL	Standard Deviation 15.992
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	125.27 mg/dL	Standard Deviation 20.33
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	131.92 mg/dL	Standard Deviation 21.922
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	132.50 mg/dL	Standard Deviation 19.449
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	129.32 mg/dL	Standard Deviation 20.86
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	135.90 mg/dL	Standard Deviation 24.697
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	130.31 mg/dL	Standard Deviation 21.031
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	126.23 mg/dL	Standard Deviation 14.356
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	132.08 mg/dL	Standard Deviation 21.244
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	126.38 mg/dL	Standard Deviation 21.478
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	127.92 mg/dL	Standard Deviation 20.392
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	133.92 mg/dL	Standard Deviation 23.24
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	127.76 mg/dL	Standard Deviation 17.973
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	129.60 mg/dL	Standard Deviation 23.381
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	118.88 mg/dL	Standard Deviation 22.883
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	129.28 mg/dL	Standard Deviation 24.576
Atorvastatin + PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	130.35 mg/dL	Standard Deviation 22.28
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	99.27 mg/dL	Standard Deviation 26.705
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	135.36 mg/dL	Standard Deviation 24.745
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	111.50 mg/dL	Standard Deviation 23.118
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	105.86 mg/dL	Standard Deviation 21.07
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	102.64 mg/dL	Standard Deviation 19.458
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	101.68 mg/dL	Standard Deviation 21.825
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	107.50 mg/dL	Standard Deviation 23.299
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	103.05 mg/dL	Standard Deviation 26.462
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	104.95 mg/dL	Standard Deviation 23.941
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	106.23 mg/dL	Standard Deviation 21.728
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	109.18 mg/dL	Standard Deviation 26.412
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	110.64 mg/dL	Standard Deviation 33.53
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	106.14 mg/dL	Standard Deviation 31.001
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	104.14 mg/dL	Standard Deviation 25.496
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	107.32 mg/dL	Standard Deviation 30.459
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	132.73 mg/dL	Standard Deviation 29.66
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	139.14 mg/dL	Standard Deviation 38.095
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	139.45 mg/dL	Standard Deviation 35.88
Atorvastatin + Ezetimibe 10 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	140.91 mg/dL	Standard Deviation 39.309
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	118.20 mg/dL	Standard Deviation 33.823
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	113.28 mg/dL	Standard Deviation 36.371
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	168.50 mg/dL	Standard Deviation 28.657
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	165.17 mg/dL	Standard Deviation 31.251
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	87.76 mg/dL	Standard Deviation 36.555
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	81.32 mg/dL	Standard Deviation 33.628
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	93.36 mg/dL	Standard Deviation 36.718
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	164.22 mg/dL	Standard Deviation 25.839
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	84.52 mg/dL	Standard Deviation 29.679
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	137.00 mg/dL	Standard Deviation 36.894
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	76.96 mg/dL	Standard Deviation 32.194
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	128.68 mg/dL	Standard Deviation 30.905
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	160.80 mg/dL	Standard Deviation 37.487
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	86.64 mg/dL	Standard Deviation 30.447
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	80.64 mg/dL	Standard Deviation 34.744
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	90.32 mg/dL	Standard Deviation 34.956
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	90.96 mg/dL	Standard Deviation 34.188
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	89.44 mg/dL	Standard Deviation 29.798
PF-04950615 50 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	93.80 mg/dL	Standard Deviation 29.672
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	61.48 mg/dL	Standard Deviation 28.511
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	154.52 mg/dL	Standard Deviation 21.715
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	57.91 mg/dL	Standard Deviation 20.889
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	80.44 mg/dL	Standard Deviation 25.366
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	87.22 mg/dL	Standard Deviation 42.031
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	102.63 mg/dL	Standard Deviation 26.577
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	63.54 mg/dL	Standard Deviation 25.072
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	60.63 mg/dL	Standard Deviation 24.315
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	60.67 mg/dL	Standard Deviation 19.257
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	158.00 mg/dL	Standard Deviation 20.004
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	61.67 mg/dL	Standard Deviation 31.175
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	64.84 mg/dL	Standard Deviation 19.882
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	140.78 mg/dL	Standard Deviation 29.645
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	65.20 mg/dL	Standard Deviation 17.97
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	57.00 mg/dL	Standard Deviation 25.719
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	120.20 mg/dL	Standard Deviation 21.352
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	67.29 mg/dL	Standard Deviation 26.527
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	130.22 mg/dL	Standard Deviation 40.707
PF-04950615 100 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	59.83 mg/dL	Standard Deviation 27.495
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	78.96 mg/dL	Standard Deviation 25.696
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	57.33 mg/dL	Standard Deviation 25.237
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	61.83 mg/dL	Standard Deviation 29.732
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	159.90 mg/dL	Standard Deviation 19.8
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	54.71 mg/dL	Standard Deviation 18.388
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	60.75 mg/dL	Standard Deviation 27.619
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	54.25 mg/dL	Standard Deviation 20.339
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	63.58 mg/dL	Standard Deviation 23.404
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	57.42 mg/dL	Standard Deviation 22.654
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	67.71 mg/dL	Standard Deviation 32.399
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	53.39 mg/dL	Standard Deviation 20.954
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	77.08 mg/dL	Standard Deviation 25.943
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	96.50 mg/dL	Standard Deviation 36.13
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	103.08 mg/dL	Standard Deviation 34.759
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	114.63 mg/dL	Standard Deviation 30.177
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	137.13 mg/dL	Standard Deviation 32.817
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	119.54 mg/dL	Standard Deviation 32.896
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	55.75 mg/dL	Standard Deviation 26.272
PF-04950615 150 mg	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	59.29 mg/dL	Standard Deviation 28.406
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 141	163.52 mg/dL	Standard Deviation 22.224
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 5	165.09 mg/dL	Standard Deviation 22.88
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 50	158.83 mg/dL	Standard Deviation 17.031
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 22	166.04 mg/dL	Standard Deviation 15.741
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 106	155.57 mg/dL	Standard Deviation 17.01
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Baseline	155.22 mg/dL	Standard Deviation 23.096
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 29	168.14 mg/dL	Standard Deviation 24.032
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 99	163.70 mg/dL	Standard Deviation 17.778
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 43	167.30 mg/dL	Standard Deviation 21.85
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 155	158.17 mg/dL	Standard Deviation 15.135
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 36	154.00 mg/dL	Standard Deviation 22.815
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 85	151.30 mg/dL	Standard Deviation 21.137
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 71	156.70 mg/dL	Standard Deviation 25.663
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 8	167.22 mg/dL	Standard Deviation 23.537
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 127	161.17 mg/dL	Standard Deviation 24.383
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 15	165.39 mg/dL	Standard Deviation 21.148
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 113	153.30 mg/dL	Standard Deviation 16.255
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 169	168.55 mg/dL	Standard Deviation 19.767
PF-04950615 Placebo	Low Density Lipoprotein-Cholesterol (LDL-C)	Day 57	152.91 mg/dL	Standard Deviation 15.395

Secondary

Maximum Observed Plasma Concentration (Cmax) of PF-04950615

This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hr post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Population: The PK parameter analysis population included participants with full PK sampling in FAS who had at least 1 of the PF-04950615 PK parameters of interest. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose	3.173 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 61
Atorvastatin + PF-04950615 50 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Multiple dose	6.197 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 36
Atorvastatin + PF-04950615 100 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose	5.074 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 50
Atorvastatin + PF-04950615 100 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Multiple dose	8.343 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 119
Atorvastatin + PF-04950615 150 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose	7.382 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 45
Atorvastatin + PF-04950615 150 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Multiple dose	21.91 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 76
Atorvastatin + PF-04950615 Placebo	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose	2.994 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 44
Atorvastatin + PF-04950615 Placebo	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Multiple dose	5.874 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 55
Atorvastatin + Ezetimibe 10 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose	4.744 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 47
Atorvastatin + Ezetimibe 10 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Multiple dose	12.22 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 29
PF-04950615 50 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Single dose	7.726 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 42
PF-04950615 50 mg	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	Multiple dose	23.64 microgram per milliliter (mcg/mL)	Geometric Coefficient of Variation 88

Secondary

Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615

This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	2.176 mcg/mL	Geometric Coefficient of Variation 65
Atorvastatin + PF-04950615 100 mg	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	4.041 mcg/mL	Geometric Coefficient of Variation 147
Atorvastatin + PF-04950615 150 mg	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	12.95 mcg/mL	Geometric Coefficient of Variation 94
Atorvastatin + PF-04950615 Placebo	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	2.858 mcg/mL	Geometric Coefficient of Variation 64
Atorvastatin + Ezetimibe 10 mg	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	6.571 mcg/mL	Geometric Coefficient of Variation 40
PF-04950615 50 mg	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615	13.47 mcg/mL	Geometric Coefficient of Variation 139

Secondary

Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	113.52 mg/dL	Standard Deviation 28.259
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	64.04 mg/dL	Standard Deviation 24.315
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	155.48 mg/dL	Standard Deviation 28.791
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	77.28 mg/dL	Standard Deviation 25.268
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	79.64 mg/dL	Standard Deviation 23.937
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	82.50 mg/dL	Standard Deviation 24.128
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	81.83 mg/dL	Standard Deviation 28.164
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	149.17 mg/dL	Standard Deviation 29.556
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	95.68 mg/dL	Standard Deviation 27.248
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	81.08 mg/dL	Standard Deviation 26.644
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	59.92 mg/dL	Standard Deviation 17.814
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	88.56 mg/dL	Standard Deviation 28.234
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	75.76 mg/dL	Standard Deviation 23.552
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	66.20 mg/dL	Standard Deviation 21.848
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	159.58 mg/dL	Standard Deviation 29.033
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	149.60 mg/dL	Standard Deviation 26.876
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	134.80 mg/dL	Standard Deviation 24.1
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	69.92 mg/dL	Standard Deviation 23.315
Atorvastatin + PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	93.24 mg/dL	Standard Deviation 22.966
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	58.92 mg/dL	Standard Deviation 23.638
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	153.75 mg/dL	Standard Deviation 25.535
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	53.38 mg/dL	Standard Deviation 22.329
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	58.08 mg/dL	Standard Deviation 26.357
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	63.54 mg/dL	Standard Deviation 25.086
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	71.79 mg/dL	Standard Deviation 26.662
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	51.50 mg/dL	Standard Deviation 23.178
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	60.04 mg/dL	Standard Deviation 23.665
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	144.83 mg/dL	Standard Deviation 26.836
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	79.33 mg/dL	Standard Deviation 27.14
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	58.13 mg/dL	Standard Deviation 23.709
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	66.63 mg/dL	Standard Deviation 30.685
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	52.58 mg/dL	Standard Deviation 21.847
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	142.08 mg/dL	Standard Deviation 32.188
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	77.88 mg/dL	Standard Deviation 27.299
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	155.54 mg/dL	Standard Deviation 20.706
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	66.04 mg/dL	Standard Deviation 29.895
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	117.42 mg/dL	Standard Deviation 37.408
Atorvastatin + PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	97.78 mg/dL	Standard Deviation 25.034
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	51.09 mg/dL	Standard Deviation 14.82
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	48.65 mg/dL	Standard Deviation 13.11
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	44.26 mg/dL	Standard Deviation 9.186
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	98.48 mg/dL	Standard Deviation 15.003
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	154.71 mg/dL	Standard Deviation 22.511
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	133.30 mg/dL	Standard Deviation 30.526
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	76.17 mg/dL	Standard Deviation 15.222
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	119.83 mg/dL	Standard Deviation 42.083
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	57.96 mg/dL	Standard Deviation 16.134
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	85.09 mg/dL	Standard Deviation 41.318
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	48.26 mg/dL	Standard Deviation 10.037
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	55.78 mg/dL	Standard Deviation 27.153
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	148.52 mg/dL	Standard Deviation 27.77
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	54.14 mg/dL	Standard Deviation 28.648
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	44.96 mg/dL	Standard Deviation 10.598
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	60.05 mg/dL	Standard Deviation 35.754
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	51.46 mg/dL	Standard Deviation 14.926
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	49.87 mg/dL	Standard Deviation 24.464
Atorvastatin + PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	45.65 mg/dL	Standard Deviation 11.276
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	159.46 mg/dL	Standard Deviation 25.221
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	160.04 mg/dL	Standard Deviation 19.838
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	156.36 mg/dL	Standard Deviation 18.83
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	153.15 mg/dL	Standard Deviation 19.601
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	158.60 mg/dL	Standard Deviation 22.504
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	162.35 mg/dL	Standard Deviation 20.558
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	155.52 mg/dL	Standard Deviation 20.49
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	163.90 mg/dL	Standard Deviation 25.271
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	161.54 mg/dL	Standard Deviation 22.089
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	157.31 mg/dL	Standard Deviation 16.79
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	162.16 mg/dL	Standard Deviation 29.067
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	154.92 mg/dL	Standard Deviation 22.289
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	157.62 mg/dL	Standard Deviation 22.608
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	161.80 mg/dL	Standard Deviation 21.96
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	154.08 mg/dL	Standard Deviation 19.378
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	159.16 mg/dL	Standard Deviation 20.163
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	146.36 mg/dL	Standard Deviation 23.787
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	159.12 mg/dL	Standard Deviation 20.961
Atorvastatin + PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	161.23 mg/dL	Standard Deviation 22.059
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	126.68 mg/dL	Standard Deviation 28.919
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	165.86 mg/dL	Standard Deviation 26.655
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	140.77 mg/dL	Standard Deviation 26.324
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	131.52 mg/dL	Standard Deviation 23.712
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	130.27 mg/dL	Standard Deviation 19.489
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	130.59 mg/dL	Standard Deviation 24.595
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	133.41 mg/dL	Standard Deviation 30.589
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	129.32 mg/dL	Standard Deviation 29.451
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	132.05 mg/dL	Standard Deviation 29.005
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	130.64 mg/dL	Standard Deviation 25.964
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	134.91 mg/dL	Standard Deviation 30.239
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	139.05 mg/dL	Standard Deviation 36.247
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	133.68 mg/dL	Standard Deviation 34.79
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	130.82 mg/dL	Standard Deviation 29.301
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	131.41 mg/dL	Standard Deviation 32.515
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	163.36 mg/dL	Standard Deviation 33.835
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	170.41 mg/dL	Standard Deviation 37.185
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	169.41 mg/dL	Standard Deviation 37.377
Atorvastatin + Ezetimibe 10 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	174.45 mg/dL	Standard Deviation 41.877
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	142.84 mg/dL	Standard Deviation 36.478
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	138.40 mg/dL	Standard Deviation 38.794
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	193.88 mg/dL	Standard Deviation 33.789
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	190.96 mg/dL	Standard Deviation 34.453
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	112.60 mg/dL	Standard Deviation 37.446
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	101.80 mg/dL	Standard Deviation 35.249
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	115.52 mg/dL	Standard Deviation 38.434
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	188.72 mg/dL	Standard Deviation 30.222
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	107.76 mg/dL	Standard Deviation 31.232
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	164.60 mg/dL	Standard Deviation 38.791
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	101.60 mg/dL	Standard Deviation 36.427
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	154.36 mg/dL	Standard Deviation 35.666
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	187.96 mg/dL	Standard Deviation 41.528
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	110.40 mg/dL	Standard Deviation 30.783
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	103.72 mg/dL	Standard Deviation 37.651
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	115.36 mg/dL	Standard Deviation 37.861
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	115.48 mg/dL	Standard Deviation 36.001
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	111.80 mg/dL	Standard Deviation 30.993
PF-04950615 50 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	118.36 mg/dL	Standard Deviation 32.875
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	83.00 mg/dL	Standard Deviation 27.632
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	183.52 mg/dL	Standard Deviation 37.346
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	80.30 mg/dL	Standard Deviation 20.448
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	103.16 mg/dL	Standard Deviation 26.742
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	113.13 mg/dL	Standard Deviation 46.332
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	123.25 mg/dL	Standard Deviation 25.378
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	86.08 mg/dL	Standard Deviation 30.679
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	82.25 mg/dL	Standard Deviation 22.283
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	81.83 mg/dL	Standard Deviation 15.898
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	182.86 mg/dL	Standard Deviation 22.842
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	85.29 mg/dL	Standard Deviation 30.599
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	88.16 mg/dL	Standard Deviation 23.005
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	164.83 mg/dL	Standard Deviation 34.193
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	90.68 mg/dL	Standard Deviation 25.61
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	77.87 mg/dL	Standard Deviation 23.47
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	143.24 mg/dL	Standard Deviation 23.52
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	88.71 mg/dL	Standard Deviation 24.172
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	154.17 mg/dL	Standard Deviation 45.14
PF-04950615 100 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	78.00 mg/dL	Standard Deviation 27.144
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	102.75 mg/dL	Standard Deviation 33.666
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	76.13 mg/dL	Standard Deviation 22.793
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	82.08 mg/dL	Standard Deviation 27.547
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	182.17 mg/dL	Standard Deviation 21.217
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	72.17 mg/dL	Standard Deviation 18.874
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	79.42 mg/dL	Standard Deviation 26.345
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	74.50 mg/dL	Standard Deviation 19.496
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	82.46 mg/dL	Standard Deviation 20.659
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	74.75 mg/dL	Standard Deviation 22.115
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	88.29 mg/dL	Standard Deviation 28.964
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	72.35 mg/dL	Standard Deviation 20.232
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	99.13 mg/dL	Standard Deviation 22.099
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	122.73 mg/dL	Standard Deviation 29.183
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	128.96 mg/dL	Standard Deviation 44.304
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	137.50 mg/dL	Standard Deviation 28.77
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	162.65 mg/dL	Standard Deviation 40.341
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	144.58 mg/dL	Standard Deviation 40.902
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	73.21 mg/dL	Standard Deviation 24.568
PF-04950615 150 mg	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	78.96 mg/dL	Standard Deviation 27.207
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 141	191.09 mg/dL	Standard Deviation 24.978
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 5	189.36 mg/dL	Standard Deviation 24.432
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 50	186.70 mg/dL	Standard Deviation 20.22
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 22	192.09 mg/dL	Standard Deviation 18.757
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 106	183.35 mg/dL	Standard Deviation 19.664
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Baseline	181.17 mg/dL	Standard Deviation 23.577
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 29	192.59 mg/dL	Standard Deviation 23.425
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 99	190.52 mg/dL	Standard Deviation 20.551
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 43	194.30 mg/dL	Standard Deviation 22.876
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 155	184.48 mg/dL	Standard Deviation 18.03
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 36	184.74 mg/dL	Standard Deviation 25.913
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 85	175.17 mg/dL	Standard Deviation 24.398
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 71	185.96 mg/dL	Standard Deviation 28.798
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 8	193.70 mg/dL	Standard Deviation 20.424
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 127	191.78 mg/dL	Standard Deviation 28.623
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 15	191.61 mg/dL	Standard Deviation 22.845
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 113	180.65 mg/dL	Standard Deviation 16.489
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 169	193.59 mg/dL	Standard Deviation 17.816
PF-04950615 Placebo	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)	Day 57	180.17 mg/dL	Standard Deviation 17.167

Secondary

Number of Participants With Anti-Drug Antibody (ADA) Response

Participants tested positive for ADA response on at least one post-baseline visit were reported. Participants with ADA titer level \>=6.23 for PF-04950615 were considered ADA positive.

Time frame: Baseline up to Day 169

Population: Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment. This outcome measure was planned to be analyzed for all the reporting groups except for Atorvastatin + Ezetimibe 10 mg.

Arm	Measure	Value (NUMBER)
Atorvastatin + PF-04950615 50 mg	Number of Participants With Anti-Drug Antibody (ADA) Response	14 participants
Atorvastatin + PF-04950615 100 mg	Number of Participants With Anti-Drug Antibody (ADA) Response	6 participants
Atorvastatin + PF-04950615 150 mg	Number of Participants With Anti-Drug Antibody (ADA) Response	14 participants
Atorvastatin + Ezetimibe 10 mg	Number of Participants With Anti-Drug Antibody (ADA) Response	13 participants
PF-04950615 50 mg	Number of Participants With Anti-Drug Antibody (ADA) Response	16 participants
PF-04950615 100 mg	Number of Participants With Anti-Drug Antibody (ADA) Response	11 participants

Secondary

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are events between first dose of study drug and up to Day 169 that were absent before treatment or that worsened relative to pretreatment state. Adverse events included treatment emergent injection site adverse events and any clinically significant abnormal laboratory value.

Time frame: Baseline up to Day 169

Population: Safety analysis set included all randomized and non-randomized participants who were administered at least 1 dose of study treatment.

Arm	Measure	Group	Value (NUMBER)
Atorvastatin + PF-04950615 50 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	17 participants
Atorvastatin + PF-04950615 50 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	1 participants
Atorvastatin + PF-04950615 100 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	16 participants
Atorvastatin + PF-04950615 100 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	0 participants
Atorvastatin + PF-04950615 150 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	13 participants
Atorvastatin + PF-04950615 150 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	0 participants
Atorvastatin + PF-04950615 Placebo	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	13 participants
Atorvastatin + PF-04950615 Placebo	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	1 participants
Atorvastatin + Ezetimibe 10 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	5 participants
Atorvastatin + Ezetimibe 10 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04950615 50 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04950615 50 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	16 participants
PF-04950615 100 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	1 participants
PF-04950615 100 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	16 participants
PF-04950615 150 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	15 participants
PF-04950615 150 mg	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04950615 Placebo	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	AEs	11 participants
PF-04950615 Placebo	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)	SAEs	0 participants

Secondary

Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter

LDL-C is cholesterol in the bloodstream that is carried by low density lipoprotein. Fasting was required at least 10 hours before blood sample collection.

Time frame: Baseline up to Day 113

Population: FAS included all the participants who were randomized and administered at least 1 dose of study treatment. The outcome measure was planned to be analyzed for all the reporting groups except Atorvastatin + Ezetimibe 10 mg.

Arm	Measure	Group	Value (NUMBER)
Atorvastatin + PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
Atorvastatin + PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	100.0 percentage of participants
Atorvastatin + PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	96.0 percentage of participants
Atorvastatin + PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	84.0 percentage of participants
Atorvastatin + PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	12.0 percentage of participants
Atorvastatin + PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	66.7 percentage of participants
Atorvastatin + PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	100.0 percentage of participants
Atorvastatin + PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	100.0 percentage of participants
Atorvastatin + PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	91.7 percentage of participants
Atorvastatin + PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	4.2 percentage of participants
Atorvastatin + PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	58.3 percentage of participants
Atorvastatin + PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	100.0 percentage of participants
Atorvastatin + PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
Atorvastatin + PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	100.0 percentage of participants
Atorvastatin + PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	95.8 percentage of participants
Atorvastatin + PF-04950615 Placebo	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	0.0 percentage of participants
Atorvastatin + PF-04950615 Placebo	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	23.1 percentage of participants
Atorvastatin + PF-04950615 Placebo	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
Atorvastatin + PF-04950615 Placebo	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	0.0 percentage of participants
Atorvastatin + PF-04950615 Placebo	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	0.0 percentage of participants
Atorvastatin + Ezetimibe 10 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	12.0 percentage of participants
Atorvastatin + Ezetimibe 10 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
Atorvastatin + Ezetimibe 10 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	0.0 percentage of participants
Atorvastatin + Ezetimibe 10 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	64.0 percentage of participants
Atorvastatin + Ezetimibe 10 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	92.0 percentage of participants
PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	0.0 percentage of participants
PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	100.0 percentage of participants
PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	36.0 percentage of participants
PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
PF-04950615 50 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	92.0 percentage of participants
PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	41.7 percentage of participants
PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	20.8 percentage of participants
PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	87.5 percentage of participants
PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
PF-04950615 100 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	100.0 percentage of participants
PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <10 mg/dL	0.0 percentage of participants
PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <25 mg/dL	0.0 percentage of participants
PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <100 mg/dL	4.3 percentage of participants
PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <40 mg/dL	0.0 percentage of participants
PF-04950615 150 mg	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter	LDL-C <70 mg/dL	0.0 percentage of participants

Secondary

Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	0.87 percent change	Standard Deviation 7.002
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	1.93 percent change	Standard Deviation 6.789
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	4.20 percent change	Standard Deviation 7.438
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	4.82 percent change	Standard Deviation 8.766
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	3.26 percent change	Standard Deviation 8.418
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	3.13 percent change	Standard Deviation 8.663
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-6.44 percent change	Standard Deviation 6.252
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-5.16 percent change	Standard Deviation 8.106
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-0.34 percent change	Standard Deviation 7.749
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	0.15 percent change	Standard Deviation 7.819
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	0.13 percent change	Standard Deviation 7.013
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-3.82 percent change	Standard Deviation 8.033
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	1.53 percent change	Standard Deviation 6.572
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-1.00 percent change	Standard Deviation 8.245
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	0.44 percent change	Standard Deviation 8.673
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-1.84 percent change	Standard Deviation 5.923
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 85	-9.10 percent change	Standard Deviation 6.738
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113	Change at Day 113	-6.55 percent change	Standard Deviation 6.903

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [6.976, 14.597]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [5.206, 12.932]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.01495% CI: [0.541, 9.178]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [3.037, 11.624]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [4.856, 13.293]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.0195% CI: [0.693, 7.642]Mixed Models Analysis

Secondary

Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-0.85 percent change	Standard Deviation 7.387
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-0.21 percent change	Standard Deviation 6.972
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	0.17 percent change	Standard Deviation 8.699
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	0.13 percent change	Standard Deviation 7.974
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-1.34 percent change	Standard Deviation 7.672
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-1.99 percent change	Standard Deviation 7.403
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-2.93 percent change	Standard Deviation 5.741
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-2.77 percent change	Standard Deviation 11.234
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	3.13 percent change	Standard Deviation 8.288
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	1.48 percent change	Standard Deviation 6.776
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-1.94 percent change	Standard Deviation 6.337
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-2.87 percent change	Standard Deviation 7.788
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	2.64 percent change	Standard Deviation 7.315
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	1.34 percent change	Standard Deviation 10.779
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	0.98 percent change	Standard Deviation 10.565
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	0.39 percent change	Standard Deviation 9.526
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 85	-4.97 percent change	Standard Deviation 9.262
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113	Change at Day 113	-3.29 percent change	Standard Deviation 10.137

Comparison: Day 113 : Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.18595% CI: [-2.6334, 6.9988]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.14795% CI: [-2.1608, 7.0724]Mixed Models Analysis

Secondary

Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-44.37 percent change	Standard Deviation 16.358
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-43.21 percent change	Standard Deviation 13.147
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-58.47 percent change	Standard Deviation 19.271
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-55.05 percent change	Standard Deviation 19.756
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-63.09 percent change	Standard Deviation 16.24
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-60.32 percent change	Standard Deviation 15.924
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	5.51 percent change	Standard Deviation 12.823
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-2.03 percent change	Standard Deviation 14.326
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-9.13 percent change	Standard Deviation 16.695
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-14.00 percent change	Standard Deviation 14.205
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-34.11 percent change	Standard Deviation 18.505
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-32.09 percent change	Standard Deviation 18.463
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-49.84 percent change	Standard Deviation 13.744
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-50.97 percent change	Standard Deviation 16.38
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	-55.16 percent change	Standard Deviation 11.927
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	-53.65 percent change	Standard Deviation 13.386
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 85	10.41 percent change	Standard Deviation 15.319
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113	Change at Day 113	11.47 percent change	Standard Deviation 16.25

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-56.83019, -42.01803]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-74.16086, -59.10681]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-79.30431, -64.15371]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-51.35899, -35.77293]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-70.02607, -54.67245]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-72.65818, -57.47415]Mixed Models Analysis

Secondary

Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-44.30 percent change	Standard Deviation 15.675
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-42.64 percent change	Standard Deviation 11.864
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-57.02 percent change	Standard Deviation 17.985
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-53.45 percent change	Standard Deviation 18.449
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-62.31 percent change	Standard Deviation 15.684
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-59.48 percent change	Standard Deviation 15.32
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-1.77 percent change	Standard Deviation 10.567
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-7.54 percent change	Standard Deviation 11.662
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-9.97 percent change	Standard Deviation 14.426
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-14.17 percent change	Standard Deviation 12.713
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-34.66 percent change	Standard Deviation 16.214
PF-04950615 50 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-35.16 percent change	Standard Deviation 15.906
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-49.10 percent change	Standard Deviation 14.474
PF-04950615 100 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-51.62 percent change	Standard Deviation 16.289
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-55.31 percent change	Standard Deviation 11.06
PF-04950615 150 mg	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	-54.88 percent change	Standard Deviation 12.109
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 85	-0.13 percent change	Standard Deviation 12.144
PF-04950615 Placebo	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113	Change at Day 113	3.43 percent change	Standard Deviation 12.038

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-50.347, -36.183]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-65.167, -50.758]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-72.039, -57.419]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-43.451, -29.405]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-60.325, -46.267]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-62.436, -48.542]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-65.64, -51.6]Mixed Models Analysis

Secondary

Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113

HDL-C is cholesterol in the bloodstream that is carried by high density lipoprotein. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	7.26 percent change	Standard Deviation 10.914
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	7.39 percent change	Standard Deviation 11.623
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	9.46 percent change	Standard Deviation 11.132
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	11.97 percent change	Standard Deviation 13.385
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	5.86 percent change	Standard Deviation 9.988
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	5.27 percent change	Standard Deviation 12.612
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-7.31 percent change	Standard Deviation 7.254
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	-4.83 percent change	Standard Deviation 9.919
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	5.42 percent change	Standard Deviation 10.501
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	6.31 percent change	Standard Deviation 9.989
PF-04950615 50 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	1.86 percent change	Standard Deviation 11.617
PF-04950615 50 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-3.10 percent change	Standard Deviation 10.471
PF-04950615 100 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	2.35 percent change	Standard Deviation 10.959
PF-04950615 100 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	2.93 percent change	Standard Deviation 11.259
PF-04950615 150 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	2.35 percent change	Standard Deviation 12.101
PF-04950615 150 mg	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	1.05 percent change	Standard Deviation 10.017
PF-04950615 Placebo	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 85	-7.16 percent change	Standard Deviation 8.271
PF-04950615 Placebo	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113	Change at Day 113	-7.53 percent change	Standard Deviation 7.966

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.00195% CI: [3.252, 14.544]Mixed Models Analysis

Secondary

Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113

Lp(a) is a lipoprotein subclass which consists of an LDL-like particle and the specific apolipoprotein(a). Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-47.11 percent change	Standard Deviation 20.802
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-42.30 percent change	Standard Deviation 19.223
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-58.53 percent change	Standard Deviation 22.181
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-57.94 percent change	Standard Deviation 22.317
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-46.51 percent change	Standard Deviation 63.192
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-59.42 percent change	Standard Deviation 21.689
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-19.37 percent change	Standard Deviation 25.16
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-24.35 percent change	Standard Deviation 21.348
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-15.22 percent change	Standard Deviation 23.532
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-18.64 percent change	Standard Deviation 18.3
PF-04950615 50 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-45.26 percent change	Standard Deviation 22.49
PF-04950615 50 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-37.85 percent change	Standard Deviation 27.223
PF-04950615 100 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-47.60 percent change	Standard Deviation 19.448
PF-04950615 100 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-37.29 percent change	Standard Deviation 24.552
PF-04950615 150 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-43.37 percent change	Standard Deviation 39.755
PF-04950615 150 mg	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-49.77 percent change	Standard Deviation 25.417
PF-04950615 Placebo	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 85	-18.40 percent change	Standard Deviation 30.139
PF-04950615 Placebo	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113	Change at Day 113	-15.89 percent change	Standard Deviation 36.642

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-48.465, -17.2289]Mixed Models Analysis

Secondary

Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113

Non-HDL-C calculated as total cholesterol minus HDL cholesterol. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-50.98 percent change	Standard Deviation 15.662
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-48.56 percent change	Standard Deviation 12.284
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-60.62 percent change	Standard Deviation 17.746
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-58.57 percent change	Standard Deviation 17.97
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-67.69 percent change	Standard Deviation 14.462
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-63.92 percent change	Standard Deviation 15.872
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-4.77 percent change	Standard Deviation 11.716
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-10.59 percent change	Standard Deviation 11.977
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-16.20 percent change	Standard Deviation 16.334
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-20.67 percent change	Standard Deviation 15.155
PF-04950615 50 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-40.19 percent change	Standard Deviation 17.244
PF-04950615 50 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-41.11 percent change	Standard Deviation 16.193
PF-04950615 100 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-54.54 percent change	Standard Deviation 13.671
PF-04950615 100 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-56.87 percent change	Standard Deviation 14.745
PF-04950615 150 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-60.17 percent change	Standard Deviation 10.493
PF-04950615 150 mg	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	-60.43 percent change	Standard Deviation 11.07
PF-04950615 Placebo	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 85	-2.49 percent change	Standard Deviation 12.951
PF-04950615 Placebo	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113	Change at Day 113	0.88 percent change	Standard Deviation 13.236

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-53.671, -39.874]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-66.257, -52.143]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-74.007, -59.73]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-47.195, -32.908]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-63.135, -48.882]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-64.618, -50.533]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-68.477, -54.134]Mixed Models Analysis

Secondary

Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-36.26 percent change	Standard Deviation 11.313
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-34.28 percent change	Standard Deviation 8.799
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-42.64 percent change	Standard Deviation 13.31
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-40.55 percent change	Standard Deviation 13.471
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-48.22 percent change	Standard Deviation 11.066
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-45.58 percent change	Standard Deviation 12.422
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-5.47 percent change	Standard Deviation 9.038
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-9.18 percent change	Standard Deviation 9.204
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-10.85 percent change	Standard Deviation 11.295
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-14.02 percent change	Standard Deviation 10.9
PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-30.50 percent change	Standard Deviation 13.212
PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-32.56 percent change	Standard Deviation 12.011
PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-40.27 percent change	Standard Deviation 11.798
PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-41.98 percent change	Standard Deviation 12.224
PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-45.28 percent change	Standard Deviation 9.539
PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-45.71 percent change	Standard Deviation 9.786
PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 85	-3.82 percent change	Standard Deviation 10.484
PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113	Change at Day 113	-1.62 percent change	Standard Deviation 8.941

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-47.299, -35.445]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-49.647, -38.247]Mixed Models Analysis

Secondary

Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-39.99 percent change	Standard Deviation 12.892
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-38.20 percent change	Standard Deviation 10.463
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-47.06 percent change	Standard Deviation 15.152
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-46.04 percent change	Standard Deviation 15.705
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-50.43 percent change	Standard Deviation 13.358
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-47.68 percent change	Standard Deviation 13.195
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	2.19 percent change	Standard Deviation 10.328
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-3.81 percent change	Standard Deviation 12.537
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-14.65 percent change	Standard Deviation 14.74
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-18.57 percent change	Standard Deviation 13.541
PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-31.07 percent change	Standard Deviation 14.77
PF-04950615 50 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-29.51 percent change	Standard Deviation 16.2
PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-41.49 percent change	Standard Deviation 10.52
PF-04950615 100 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-43.25 percent change	Standard Deviation 12.569
PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	-45.74 percent change	Standard Deviation 11.961
PF-04950615 150 mg	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	-45.65 percent change	Standard Deviation 12.114
PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 85	3.81 percent change	Standard Deviation 10.643
PF-04950615 Placebo	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113	Change at Day 113	6.98 percent change	Standard Deviation 12.436

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-47.55052, -36.30778]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-56.81235, -45.35973]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-61.29424, -49.73777]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-39.41376, -27.19373]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-53.92668, -41.77751]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-54.6606, -42.65313]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-58.01968, -45.7246]Mixed Models Analysis

Secondary

Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113

Triglycerides are a type of fat circulating in the blood and account for the majority of the fats circulating in the blood. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-21.00 percent change	Standard Deviation 31.109
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-14.44 percent change	Standard Deviation 26.916
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-16.85 percent change	Standard Deviation 28.672
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-27.65 percent change	Standard Deviation 26.827
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-23.38 percent change	Standard Deviation 24.421
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-17.70 percent change	Standard Deviation 29.263
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	3.74 percent change	Standard Deviation 27.803
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-3.82 percent change	Standard Deviation 36.247
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-5.20 percent change	Standard Deviation 23.919
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-15.23 percent change	Standard Deviation 24.917
PF-04950615 50 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-8.31 percent change	Standard Deviation 19.5
PF-04950615 50 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	2.62 percent change	Standard Deviation 33.715
PF-04950615 100 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	1.32 percent change	Standard Deviation 37.694
PF-04950615 100 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-9.40 percent change	Standard Deviation 42.868
PF-04950615 150 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-5.21 percent change	Standard Deviation 35.698
PF-04950615 150 mg	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	-8.47 percent change	Standard Deviation 35.865
PF-04950615 Placebo	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 85	-9.33 percent change	Standard Deviation 19.235
PF-04950615 Placebo	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113	Change at Day 113	4.57 percent change	Standard Deviation 29.077

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-41.217, -10.731]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.00495% CI: [-36.665, -5.555]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-46.758, -15.31]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.79995% CI: [-10.948, 27.015]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.39895% CI: [-21.748, 16.727]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.51595% CI: [-18.668, 19.407]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.05695% CI: [-33.698, 3.629]Mixed Models Analysis

Secondary

Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113

VLDL is a type of lipoprotein made by the liver and one of the five major groups of lipoproteins, that enable fats and cholesterol to move within the water-based solution of the bloodstream. Fasting was required at least 10 hours before blood sample collection. Baseline was defined as the mean of the last two non-missing measurements collected prior to the first dose of study treatment. Both measurements must be within 10 days prior to the first dose of study treatment; if only one measurement was available 10 days prior to the first dose of study treatment, then that measurement served as the baseline value. Percent change from baseline = (\[observed value divided by baseline value\] minus 1) multiplied by 100.

Time frame: Baseline, Day 85, 113

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-17.23 percent change	Standard Deviation 35.083
Atorvastatin + PF-04950615 50 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-23.42 percent change	Standard Deviation 30.458
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-26.62 percent change	Standard Deviation 28.464
Atorvastatin + PF-04950615 100 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-22.99 percent change	Standard Deviation 25.647
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-28.96 percent change	Standard Deviation 25.281
Atorvastatin + PF-04950615 150 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-19.28 percent change	Standard Deviation 33.794
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-1.89 percent change	Standard Deviation 43.239
Atorvastatin + PF-04950615 Placebo	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	7.08 percent change	Standard Deviation 26.054
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-6.48 percent change	Standard Deviation 27.276
Atorvastatin + Ezetimibe 10 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-10.80 percent change	Standard Deviation 38.288
PF-04950615 50 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-9.72 percent change	Standard Deviation 29.006
PF-04950615 50 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-7.61 percent change	Standard Deviation 23.163
PF-04950615 100 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	5.66 percent change	Standard Deviation 76.931
PF-04950615 100 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	10.72 percent change	Standard Deviation 65.297
PF-04950615 150 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-3.54 percent change	Standard Deviation 45.821
PF-04950615 150 mg	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	-10.36 percent change	Standard Deviation 36.732
PF-04950615 Placebo	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 113	18.73 percent change	Standard Deviation 48.065
PF-04950615 Placebo	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113	Change at Day 85	-3.63 percent change	Standard Deviation 39.826

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-45.925, -17.836]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-43.571, -14.803]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: <0.00195% CI: [-54.136, -25.178]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.36695% CI: [-31.713, 22.35]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.77395% CI: [-16.774, 37.228]Mixed Models Analysis

Comparison: Day 85: Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.42295% CI: [-29.206, 23.915]Mixed Models Analysis

Comparison: Day 113:Adjusted mean difference and 2-sided 95% confidence interval were derived from the MMRM model with fixed effects for treatment, visit, baseline value, treatment by visit interaction, and baseline by visit interaction.p-value: 0.00695% CI: [-57.4, -7.485]Mixed Models Analysis

Secondary

Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =6.99 nanogram per milliliter \[ng/mL\]) to zero. Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points.

Time frame: Day 1, 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141

Population: PK concentration population included participants in FAS who have at least 1 concentration of either PF-04950615, PCSK9 or atorvastatin or its active metabolites. This outcome measure was planned to be analyzed for all the reporting groups except for Atorvastatin + Ezetimibe 10 mg.

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	3446.2 ng/mL	Standard Deviation 825.704
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	2727.0 ng/mL	Standard Deviation 635.595
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	2292.2 ng/mL	Standard Deviation 676.414
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	3326.7 ng/mL	Standard Deviation 611.79
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	2779.2 ng/mL	Standard Deviation 698.727
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	1429.8 ng/mL	Standard Deviation 599.406
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	2900.9 ng/mL	Standard Deviation 653.572
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	2539.8 ng/mL	Standard Deviation 558.369
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	736.63 ng/mL	Standard Deviation 297.087
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	3394.8 ng/mL	Standard Deviation 750.557
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	2915.1 ng/mL	Standard Deviation 711.932
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	2844.2 ng/mL	Standard Deviation 684.693
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	266.64 ng/mL	Standard Deviation 61.5494
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	2711.2 ng/mL	Standard Deviation 614.649
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	2727.3 ng/mL	Standard Deviation 710.746
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	3451.7 ng/mL	Standard Deviation 872.597
Atorvastatin + PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	2889.6 ng/mL	Standard Deviation 542.831
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	3297.3 ng/mL	Standard Deviation 701.137
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	3242.9 ng/mL	Standard Deviation 684.758
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	1382.8 ng/mL	Standard Deviation 892.457
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	3310.7 ng/mL	Standard Deviation 732.706
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	3241.2 ng/mL	Standard Deviation 724.363
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	3138.9 ng/mL	Standard Deviation 604.177
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	3224.8 ng/mL	Standard Deviation 868.76
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	3166.3 ng/mL	Standard Deviation 736.216
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	3204.8 ng/mL	Standard Deviation 699.49
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	2701.9 ng/mL	Standard Deviation 568.958
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	3297.2 ng/mL	Standard Deviation 654.384
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	3406.3 ng/mL	Standard Deviation 765.437
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	2148.7 ng/mL	Standard Deviation 1062.32
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	3198.1 ng/mL	Standard Deviation 897.565
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	261.23 ng/mL	Standard Deviation 72.3625
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	2152.6 ng/mL	Standard Deviation 451.749
Atorvastatin + PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	2919.0 ng/mL	Standard Deviation 511.959
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	3419.8 ng/mL	Standard Deviation 715.001
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	3280.5 ng/mL	Standard Deviation 727.932
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	3390.6 ng/mL	Standard Deviation 1149.17
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	1997.7 ng/mL	Standard Deviation 563.722
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	285.96 ng/mL	Standard Deviation 75.794
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	3030.7 ng/mL	Standard Deviation 607.61
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	2539.5 ng/mL	Standard Deviation 587.196
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	3291.9 ng/mL	Standard Deviation 624.935
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	2910.3 ng/mL	Standard Deviation 609.38
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	3166.5 ng/mL	Standard Deviation 663.295
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	2864.0 ng/mL	Standard Deviation 596.757
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	2851.0 ng/mL	Standard Deviation 1373.69
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	3259.6 ng/mL	Standard Deviation 754.73
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	3248.5 ng/mL	Standard Deviation 660.213
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	3391.9 ng/mL	Standard Deviation 717.922
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	3198.9 ng/mL	Standard Deviation 827.313
Atorvastatin + PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	3230.9 ng/mL	Standard Deviation 716.416
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	304.75 ng/mL	Standard Deviation 48.529
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	290.16 ng/mL	Standard Deviation 84.2168
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	295 ng/mL	Standard Deviation 71.6996
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	303.42 ng/mL	Standard Deviation 47.9418
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	276.31 ng/mL	Standard Deviation 72.3396
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	267.71 ng/mL	Standard Deviation 68.1498
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	269.19 ng/mL	Standard Deviation 66.8377
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	285.81 ng/mL	Standard Deviation 45.5315
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	303.54 ng/mL	Standard Deviation 81.0823
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	292.19 ng/mL	Standard Deviation 62.5108
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	293.38 ng/mL	Standard Deviation 66.9138
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	281.40 ng/mL	Standard Deviation 95.7562
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	326.08 ng/mL	Standard Deviation 78.8759
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	291.77 ng/mL	Standard Deviation 65.8011
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	275 ng/mL	Standard Deviation 57.6888
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	283.67 ng/mL	Standard Deviation 58.9079
Atorvastatin + PF-04950615 Placebo	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	277.69 ng/mL	Standard Deviation 70.6132
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	3148.5 ng/mL	Standard Deviation 541.23
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	228.80 ng/mL	Standard Deviation 49.9983
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	1952.5 ng/mL	Standard Deviation 527.661
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	2490.4 ng/mL	Standard Deviation 573.777
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	2590.6 ng/mL	Standard Deviation 601.052
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	3117.4 ng/mL	Standard Deviation 582.258
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	3050.0 ng/mL	Standard Deviation 534.176
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	3237.0 ng/mL	Standard Deviation 694.727
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	3278.9 ng/mL	Standard Deviation 693.207
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	2910.6 ng/mL	Standard Deviation 531.493
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	3066.8 ng/mL	Standard Deviation 693.445
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	2898.7 ng/mL	Standard Deviation 551.114
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	3119.2 ng/mL	Standard Deviation 665.408
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	3165.7 ng/mL	Standard Deviation 786.665
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	2908.4 ng/mL	Standard Deviation 639.771
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	1778.9 ng/mL	Standard Deviation 872.368
Atorvastatin + Ezetimibe 10 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	1056.5 ng/mL	Standard Deviation 545.337
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	3197.1 ng/mL	Standard Deviation 575.162
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	3302.5 ng/mL	Standard Deviation 584.658
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	2934.1 ng/mL	Standard Deviation 548.311
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	3011.2 ng/mL	Standard Deviation 578.469
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	215.50 ng/mL	Standard Deviation 43.0086
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	3149.3 ng/mL	Standard Deviation 590.228
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	3095.5 ng/mL	Standard Deviation 647.481
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	2971.6 ng/mL	Standard Deviation 669.215
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	2755.7 ng/mL	Standard Deviation 549.755
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	3030.8 ng/mL	Standard Deviation 715.193
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	1477.0 ng/mL	Standard Deviation 816.342
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	3009.8 ng/mL	Standard Deviation 685.462
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	2297.7 ng/mL	Standard Deviation 521.003
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	2556.0 ng/mL	Standard Deviation 772.015
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	1775.4 ng/mL	Standard Deviation 531.225
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	3026.4 ng/mL	Standard Deviation 708.49
PF-04950615 50 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	3001.3 ng/mL	Standard Deviation 696.256
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	2918.9 ng/mL	Standard Deviation 752.647
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	2726.7 ng/mL	Standard Deviation 616.409
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	2769.7 ng/mL	Standard Deviation 736.453
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	2566.5 ng/mL	Standard Deviation 483.133
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	2966.7 ng/mL	Standard Deviation 713.934
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	2820.3 ng/mL	Standard Deviation 693.13
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	2791.9 ng/mL	Standard Deviation 633.717
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	2683.9 ng/mL	Standard Deviation 574.842
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	2887.6 ng/mL	Standard Deviation 684.734
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	3016.9 ng/mL	Standard Deviation 772.615
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	2306.7 ng/mL	Standard Deviation 594.409
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	234.42 ng/mL	Standard Deviation 77.541
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	2787.9 ng/mL	Standard Deviation 812.792
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	2761.4 ng/mL	Standard Deviation 601.567
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	2955.6 ng/mL	Standard Deviation 678.703
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	1712.0 ng/mL	Standard Deviation 458.574
PF-04950615 100 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	2368.7 ng/mL	Standard Deviation 1106.62
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 113	222.05 ng/mL	Standard Deviation 46.0574
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 99	252.13 ng/mL	Standard Deviation 72.1011
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 50	237.40 ng/mL	Standard Deviation 68.2421
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 22	218.82 ng/mL	Standard Deviation 41.2647
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 1	210.22 ng/mL	Standard Deviation 48.5536
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 71	355.17 ng/mL	Standard Deviation 556.079
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 141	20.043 ng/mL	Standard Deviation 68.7012
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 127	249.87 ng/mL	Standard Deviation 63.2113
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 43	239.13 ng/mL	Standard Deviation 43.8782
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 106	242.23 ng/mL	Standard Deviation 59.4266
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 15	224.43 ng/mL	Standard Deviation 57.6903
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 5	240.41 ng/mL	Standard Deviation 63.093
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 85	269.61 ng/mL	Standard Deviation 201.161
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 8	240.22 ng/mL	Standard Deviation 53.5842
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 36	233.09 ng/mL	Standard Deviation 56.7693
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 57	220.13 ng/mL	Standard Deviation 66.99
PF-04950615 150 mg	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)	Day 29	230.09 ng/mL	Standard Deviation 44.1742

Secondary

Terminal Elimination Half-Life (t1/2) of PF-04950615

Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half. This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Arm	Measure	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Terminal Elimination Half-Life (t1/2) of PF-04950615	7.716 day	Standard Deviation 1.7594
Atorvastatin + PF-04950615 100 mg	Terminal Elimination Half-Life (t1/2) of PF-04950615	9.471 day	Standard Deviation 2.2889
Atorvastatin + PF-04950615 150 mg	Terminal Elimination Half-Life (t1/2) of PF-04950615	10.56 day	Standard Deviation 1.5934
Atorvastatin + PF-04950615 Placebo	Terminal Elimination Half-Life (t1/2) of PF-04950615	9.404 day	Standard Deviation 2.1454
Atorvastatin + Ezetimibe 10 mg	Terminal Elimination Half-Life (t1/2) of PF-04950615	9.570 day	Standard Deviation 2.2338
PF-04950615 50 mg	Terminal Elimination Half-Life (t1/2) of PF-04950615	9.333 day	Standard Deviation 2.7535

Secondary

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615

This outcome measure was to be analyzed in participants who received at least 1 dose of the PF-04950615.

Time frame: Single dose (Day 1: pre-dose, 24, 48, 72, 96, 120, 144, 168 hour (hr) post-dose), Multiple dose (Day 99: pre-dose, 24, 72, 120, 168, 336, 504, 672, 1008 hr post-dose)

Arm	Measure	Group	Value (MEDIAN)
Atorvastatin + PF-04950615 50 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose	4.01 day
Atorvastatin + PF-04950615 50 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Multiple dose	3.03 day
Atorvastatin + PF-04950615 100 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose	4.97 day
Atorvastatin + PF-04950615 100 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Multiple dose	2.98 day
Atorvastatin + PF-04950615 150 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose	5.94 day
Atorvastatin + PF-04950615 150 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Multiple dose	2.97 day
Atorvastatin + PF-04950615 Placebo	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose	5.94 day
Atorvastatin + PF-04950615 Placebo	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Multiple dose	2.99 day
Atorvastatin + Ezetimibe 10 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose	5.45 day
Atorvastatin + Ezetimibe 10 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Multiple dose	2.98 day
PF-04950615 50 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Single dose	6.94 day
PF-04950615 50 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	Multiple dose	4.98 day

Secondary

Total Cholesterol (TC)

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 15	154.20 mg/dL	Standard Deviation 26.011
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 169	212.96 mg/dL	Standard Deviation 29.508
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 50	120.04 mg/dL	Standard Deviation 20.687
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 57	134.16 mg/dL	Standard Deviation 25.826
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 8	149.72 mg/dL	Standard Deviation 24.979
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Baseline	214.16 mg/dL	Standard Deviation 30.658
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 36	124.12 mg/dL	Standard Deviation 22.38
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 127	193.96 mg/dL	Standard Deviation 26.253
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 99	151.24 mg/dL	Standard Deviation 31.139
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 29	141.04 mg/dL	Standard Deviation 27.355
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 113	140.63 mg/dL	Standard Deviation 26.65
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 141	209.75 mg/dL	Standard Deviation 32.446
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 43	139.40 mg/dL	Standard Deviation 23.944
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 85	135.52 mg/dL	Standard Deviation 25.161
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 106	126.40 mg/dL	Standard Deviation 29.017
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 155	208.32 mg/dL	Standard Deviation 28.912
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 22	129.28 mg/dL	Standard Deviation 22.856
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 5	169.20 mg/dL	Standard Deviation 28.586
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC)	Day 71	142.13 mg/dL	Standard Deviation 29.489
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 43	128.83 mg/dL	Standard Deviation 30.724
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 57	116.96 mg/dL	Standard Deviation 24.489
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 22	119.00 mg/dL	Standard Deviation 26.462
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 169	212.79 mg/dL	Standard Deviation 25.267
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 8	137.71 mg/dL	Standard Deviation 31.992
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 85	119.58 mg/dL	Standard Deviation 24.959
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 29	133.54 mg/dL	Standard Deviation 25.507
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 71	121.04 mg/dL	Standard Deviation 28.608
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 106	114.75 mg/dL	Standard Deviation 26.967
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 141	202.71 mg/dL	Standard Deviation 26.989
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 50	112.63 mg/dL	Standard Deviation 23.585
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 36	113.88 mg/dL	Standard Deviation 25
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 15	137.83 mg/dL	Standard Deviation 27.241
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Baseline	210.29 mg/dL	Standard Deviation 21.594
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 113	124.58 mg/dL	Standard Deviation 27.91
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 99	128.58 mg/dL	Standard Deviation 28.864
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 5	154.83 mg/dL	Standard Deviation 30.045
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 127	176.88 mg/dL	Standard Deviation 32.328
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC)	Day 155	203.83 mg/dL	Standard Deviation 24.533
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 36	107.35 mg/dL	Standard Deviation 19.59
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 15	120.75 mg/dL	Standard Deviation 25.589
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 22	112.78 mg/dL	Standard Deviation 19.247
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 113	115.17 mg/dL	Standard Deviation 30.293
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 127	147.87 mg/dL	Standard Deviation 37.486
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 99	122.36 mg/dL	Standard Deviation 36.702
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 85	109.57 mg/dL	Standard Deviation 27.611
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 141	184.09 mg/dL	Standard Deviation 38.141
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 71	113.48 mg/dL	Standard Deviation 25.056
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 155	195.26 mg/dL	Standard Deviation 31.865
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 57	104.61 mg/dL	Standard Deviation 20.045
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 169	211.00 mg/dL	Standard Deviation 31.348
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 106	118.55 mg/dL	Standard Deviation 29.987
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 50	107.74 mg/dL	Standard Deviation 22.471
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Baseline	211.71 mg/dL	Standard Deviation 23.065
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 43	113.75 mg/dL	Standard Deviation 23.167
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 5	156.91 mg/dL	Standard Deviation 22.24
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 8	136.50 mg/dL	Standard Deviation 21.364
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC)	Day 29	114.91 mg/dL	Standard Deviation 24.487
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 22	218.12 mg/dL	Standard Deviation 24.006
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 57	208.04 mg/dL	Standard Deviation 23.282
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 106	212.36 mg/dL	Standard Deviation 22.002
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 155	221.28 mg/dL	Standard Deviation 24.455
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 29	217.12 mg/dL	Standard Deviation 24.28
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 5	219.42 mg/dL	Standard Deviation 24.861
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 71	218.38 mg/dL	Standard Deviation 23.474
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 141	216.48 mg/dL	Standard Deviation 22.45
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 36	217.08 mg/dL	Standard Deviation 26.204
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 85	208.88 mg/dL	Standard Deviation 24.747
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 127	219.32 mg/dL	Standard Deviation 26.684
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 99	216.28 mg/dL	Standard Deviation 19.25
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 113	201.64 mg/dL	Standard Deviation 26.967
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 15	221.69 mg/dL	Standard Deviation 23.988
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 8	222.68 mg/dL	Standard Deviation 28.253
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Baseline	222.44 mg/dL	Standard Deviation 31.317
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 50	215.42 mg/dL	Standard Deviation 23.262
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 169	221.00 mg/dL	Standard Deviation 26.091
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC)	Day 43	214.62 mg/dL	Standard Deviation 19.179
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 106	190.27 mg/dL	Standard Deviation 28.352
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 113	191.73 mg/dL	Standard Deviation 34.189
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 127	221.18 mg/dL	Standard Deviation 32.444
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 141	229.50 mg/dL	Standard Deviation 38.48
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 155	228.86 mg/dL	Standard Deviation 37.64
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 169	234.95 mg/dL	Standard Deviation 43.216
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Baseline	222.84 mg/dL	Standard Deviation 25.395
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 5	197.77 mg/dL	Standard Deviation 25.487
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 8	190.19 mg/dL	Standard Deviation 20.856
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 15	190.50 mg/dL	Standard Deviation 20.964
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 22	190.64 mg/dL	Standard Deviation 23.768
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 29	192.41 mg/dL	Standard Deviation 31.173
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 36	187.55 mg/dL	Standard Deviation 30.803
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 43	190.86 mg/dL	Standard Deviation 28.734
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 50	189.18 mg/dL	Standard Deviation 24.209
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 57	184.14 mg/dL	Standard Deviation 31.148
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 71	192.91 mg/dL	Standard Deviation 31.288
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 85	198.82 mg/dL	Standard Deviation 36
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC)	Day 99	194.05 mg/dL	Standard Deviation 33.23
PF-04950615 50 mg	Total Cholesterol (TC)	Day 106	167.84 mg/dL	Standard Deviation 32.859
PF-04950615 50 mg	Total Cholesterol (TC)	Day 85	165.44 mg/dL	Standard Deviation 32.651
PF-04950615 50 mg	Total Cholesterol (TC)	Day 127	223.16 mg/dL	Standard Deviation 39.032
PF-04950615 50 mg	Total Cholesterol (TC)	Day 113	169.72 mg/dL	Standard Deviation 31.052
PF-04950615 50 mg	Total Cholesterol (TC)	Day 8	202.44 mg/dL	Standard Deviation 37.095
PF-04950615 50 mg	Total Cholesterol (TC)	Day 5	211.56 mg/dL	Standard Deviation 37.176
PF-04950615 50 mg	Total Cholesterol (TC)	Day 15	198.64 mg/dL	Standard Deviation 39.145
PF-04950615 50 mg	Total Cholesterol (TC)	Day 99	178.36 mg/dL	Standard Deviation 33.103
PF-04950615 50 mg	Total Cholesterol (TC)	Day 22	176.28 mg/dL	Standard Deviation 36.51
PF-04950615 50 mg	Total Cholesterol (TC)	Day 29	176.36 mg/dL	Standard Deviation 41.26
PF-04950615 50 mg	Total Cholesterol (TC)	Day 43	171.96 mg/dL	Standard Deviation 40.287
PF-04950615 50 mg	Total Cholesterol (TC)	Baseline	245.94 mg/dL	Standard Deviation 30.425
PF-04950615 50 mg	Total Cholesterol (TC)	Day 50	161.00 mg/dL	Standard Deviation 37.653
PF-04950615 50 mg	Total Cholesterol (TC)	Day 169	254.17 mg/dL	Standard Deviation 32.859
PF-04950615 50 mg	Total Cholesterol (TC)	Day 57	158.96 mg/dL	Standard Deviation 39.046
PF-04950615 50 mg	Total Cholesterol (TC)	Day 155	250.00 mg/dL	Standard Deviation 34.453
PF-04950615 50 mg	Total Cholesterol (TC)	Day 71	174.64 mg/dL	Standard Deviation 37.758
PF-04950615 50 mg	Total Cholesterol (TC)	Day 36	163.48 mg/dL	Standard Deviation 39.528
PF-04950615 50 mg	Total Cholesterol (TC)	Day 141	247.36 mg/dL	Standard Deviation 40.025
PF-04950615 100 mg	Total Cholesterol (TC)	Day 99	149.83 mg/dL	Standard Deviation 33.78
PF-04950615 100 mg	Total Cholesterol (TC)	Baseline	243.26 mg/dL	Standard Deviation 21.967
PF-04950615 100 mg	Total Cholesterol (TC)	Day 141	217.43 mg/dL	Standard Deviation 43.351
PF-04950615 100 mg	Total Cholesterol (TC)	Day 106	142.26 mg/dL	Standard Deviation 32.265
PF-04950615 100 mg	Total Cholesterol (TC)	Day 43	151.80 mg/dL	Standard Deviation 23.638
PF-04950615 100 mg	Total Cholesterol (TC)	Day 29	153.20 mg/dL	Standard Deviation 25.762
PF-04950615 100 mg	Total Cholesterol (TC)	Day 36	147.08 mg/dL	Standard Deviation 25.568
PF-04950615 100 mg	Total Cholesterol (TC)	Day 169	245.57 mg/dL	Standard Deviation 34.103
PF-04950615 100 mg	Total Cholesterol (TC)	Day 71	146.17 mg/dL	Standard Deviation 29.736
PF-04950615 100 mg	Total Cholesterol (TC)	Day 50	145.22 mg/dL	Standard Deviation 24.814
PF-04950615 100 mg	Total Cholesterol (TC)	Day 8	184.58 mg/dL	Standard Deviation 30.935
PF-04950615 100 mg	Total Cholesterol (TC)	Day 155	227.83 mg/dL	Standard Deviation 31.438
PF-04950615 100 mg	Total Cholesterol (TC)	Day 85	141.09 mg/dL	Standard Deviation 31.318
PF-04950615 100 mg	Total Cholesterol (TC)	Day 113	146.00 mg/dL	Standard Deviation 33.889
PF-04950615 100 mg	Total Cholesterol (TC)	Day 57	148.00 mg/dL	Standard Deviation 30.107
PF-04950615 100 mg	Total Cholesterol (TC)	Day 5	203.56 mg/dL	Standard Deviation 28.777
PF-04950615 100 mg	Total Cholesterol (TC)	Day 15	165.48 mg/dL	Standard Deviation 30.456
PF-04950615 100 mg	Total Cholesterol (TC)	Day 127	176.74 mg/dL	Standard Deviation 46.917
PF-04950615 100 mg	Total Cholesterol (TC)	Day 22	152.63 mg/dL	Standard Deviation 29.854
PF-04950615 150 mg	Total Cholesterol (TC)	Day 15	165.71 mg/dL	Standard Deviation 37.735
PF-04950615 150 mg	Total Cholesterol (TC)	Day 106	139.92 mg/dL	Standard Deviation 35.003
PF-04950615 150 mg	Total Cholesterol (TC)	Baseline	244.19 mg/dL	Standard Deviation 29.987
PF-04950615 150 mg	Total Cholesterol (TC)	Day 85	134.17 mg/dL	Standard Deviation 30.972
PF-04950615 150 mg	Total Cholesterol (TC)	Day 36	144.63 mg/dL	Standard Deviation 40.577
PF-04950615 150 mg	Total Cholesterol (TC)	Day 43	147.25 mg/dL	Standard Deviation 41.429
PF-04950615 150 mg	Total Cholesterol (TC)	Day 127	166.63 mg/dL	Standard Deviation 34.144
PF-04950615 150 mg	Total Cholesterol (TC)	Day 113	134.17 mg/dL	Standard Deviation 31.4
PF-04950615 150 mg	Total Cholesterol (TC)	Day 29	150.42 mg/dL	Standard Deviation 34.557
PF-04950615 150 mg	Total Cholesterol (TC)	Day 169	227.65 mg/dL	Standard Deviation 39.088
PF-04950615 150 mg	Total Cholesterol (TC)	Day 22	153.67 mg/dL	Standard Deviation 43.213
PF-04950615 150 mg	Total Cholesterol (TC)	Day 8	186.73 mg/dL	Standard Deviation 44.905
PF-04950615 150 mg	Total Cholesterol (TC)	Day 99	139.13 mg/dL	Standard Deviation 32.51
PF-04950615 150 mg	Total Cholesterol (TC)	Day 57	135.83 mg/dL	Standard Deviation 39.794
PF-04950615 150 mg	Total Cholesterol (TC)	Day 50	144.17 mg/dL	Standard Deviation 40.223
PF-04950615 150 mg	Total Cholesterol (TC)	Day 141	192.96 mg/dL	Standard Deviation 37.406
PF-04950615 150 mg	Total Cholesterol (TC)	Day 71	142.42 mg/dL	Standard Deviation 37.326
PF-04950615 150 mg	Total Cholesterol (TC)	Day 5	199.58 mg/dL	Standard Deviation 41.618
PF-04950615 150 mg	Total Cholesterol (TC)	Day 155	208.25 mg/dL	Standard Deviation 33.069
PF-04950615 Placebo	Total Cholesterol (TC)	Day 22	253.57 mg/dL	Standard Deviation 15.716
PF-04950615 Placebo	Total Cholesterol (TC)	Day 29	256.73 mg/dL	Standard Deviation 22.391
PF-04950615 Placebo	Total Cholesterol (TC)	Day 5	249.09 mg/dL	Standard Deviation 24.156
PF-04950615 Placebo	Total Cholesterol (TC)	Day 36	244.65 mg/dL	Standard Deviation 24.356
PF-04950615 Placebo	Total Cholesterol (TC)	Baseline	242.04 mg/dL	Standard Deviation 22.956
PF-04950615 Placebo	Total Cholesterol (TC)	Day 99	249.83 mg/dL	Standard Deviation 19.277
PF-04950615 Placebo	Total Cholesterol (TC)	Day 43	254.04 mg/dL	Standard Deviation 19.793
PF-04950615 Placebo	Total Cholesterol (TC)	Day 169	258.64 mg/dL	Standard Deviation 20.537
PF-04950615 Placebo	Total Cholesterol (TC)	Day 106	241.65 mg/dL	Standard Deviation 18.982
PF-04950615 Placebo	Total Cholesterol (TC)	Day 50	246.09 mg/dL	Standard Deviation 17.776
PF-04950615 Placebo	Total Cholesterol (TC)	Day 155	246.35 mg/dL	Standard Deviation 15.171
PF-04950615 Placebo	Total Cholesterol (TC)	Day 57	236.78 mg/dL	Standard Deviation 16.105
PF-04950615 Placebo	Total Cholesterol (TC)	Day 141	253.48 mg/dL	Standard Deviation 21.494
PF-04950615 Placebo	Total Cholesterol (TC)	Day 71	243.74 mg/dL	Standard Deviation 24.849
PF-04950615 Placebo	Total Cholesterol (TC)	Day 127	249.78 mg/dL	Standard Deviation 25.598
PF-04950615 Placebo	Total Cholesterol (TC)	Day 85	231.52 mg/dL	Standard Deviation 22.701
PF-04950615 Placebo	Total Cholesterol (TC)	Day 113	236.83 mg/dL	Standard Deviation 16.808
PF-04950615 Placebo	Total Cholesterol (TC)	Day 15	251.91 mg/dL	Standard Deviation 24.83
PF-04950615 Placebo	Total Cholesterol (TC)	Day 8	254.26 mg/dL	Standard Deviation 22.481

Secondary

Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	3.8140 ratio	Standard Deviation 0.77275
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	3.3776 ratio	Standard Deviation 0.67839
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	2.4688 ratio	Standard Deviation 0.50001
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	3.1372 ratio	Standard Deviation 0.81529
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	2.3148 ratio	Standard Deviation 0.44657
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.0118 ratio	Standard Deviation 0.82813
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	2.0476 ratio	Standard Deviation 0.40004
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	2.0280 ratio	Standard Deviation 0.36876
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	2.1924 ratio	Standard Deviation 0.45842
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	2.4564 ratio	Standard Deviation 0.54658
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.5433 ratio	Standard Deviation 0.67339
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	2.4020 ratio	Standard Deviation 0.54386
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	2.2428 ratio	Standard Deviation 0.5364
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	2.3724 ratio	Standard Deviation 0.52972
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.6240 ratio	Standard Deviation 0.63587
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	2.7252 ratio	Standard Deviation 0.63762
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	2.3688 ratio	Standard Deviation 0.48338
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	2.6884 ratio	Standard Deviation 0.58429
Atorvastatin + PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	2.3925 ratio	Standard Deviation 0.57023
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.6392 ratio	Standard Deviation 0.92468
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.5242 ratio	Standard Deviation 0.96281
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	2.7861 ratio	Standard Deviation 0.57451
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	2.3754 ratio	Standard Deviation 0.6255
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	1.8650 ratio	Standard Deviation 0.5062
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	3.1533 ratio	Standard Deviation 0.98795
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	2.0758 ratio	Standard Deviation 0.63508
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	3.7471 ratio	Standard Deviation 0.82852
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	2.4100 ratio	Standard Deviation 0.53023
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.0154 ratio	Standard Deviation 0.92478
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	2.0258 ratio	Standard Deviation 0.49301
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	2.0721 ratio	Standard Deviation 0.54913
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	1.9254 ratio	Standard Deviation 0.48864
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	1.9988 ratio	Standard Deviation 0.56686
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	2.1042 ratio	Standard Deviation 0.55015
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	1.9300 ratio	Standard Deviation 0.4683
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	2.2533 ratio	Standard Deviation 0.64125
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	2.1417 ratio	Standard Deviation 0.70783
Atorvastatin + PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	2.1396 ratio	Standard Deviation 0.61972
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	1.9658 ratio	Standard Deviation 0.33815
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	1.8296 ratio	Standard Deviation 0.26896
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	1.7730 ratio	Standard Deviation 0.18504
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	2.4822 ratio	Standard Deviation 0.91213
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	2.0305 ratio	Standard Deviation 0.76914
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.0078 ratio	Standard Deviation 0.91134
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	1.9691 ratio	Standard Deviation 0.52016
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	1.8561 ratio	Standard Deviation 0.49386
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.2748 ratio	Standard Deviation 0.76307
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	1.7709 ratio	Standard Deviation 0.19489
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	3.4830 ratio	Standard Deviation 0.6701
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	1.7448 ratio	Standard Deviation 0.12638
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	3.8500 ratio	Standard Deviation 0.72414
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	1.7443 ratio	Standard Deviation 0.15406
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	2.7500 ratio	Standard Deviation 0.38981
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	1.8814 ratio	Standard Deviation 0.56847
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	1.8754 ratio	Standard Deviation 0.39255
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	2.3083 ratio	Standard Deviation 0.33483
Atorvastatin + PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	1.7404 ratio	Standard Deviation 0.18627
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	3.7648 ratio	Standard Deviation 0.83515
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	3.9465 ratio	Standard Deviation 0.83527
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	3.7984 ratio	Standard Deviation 0.9003
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	3.9338 ratio	Standard Deviation 0.87409
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	3.8915 ratio	Standard Deviation 0.75155
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	4.0085 ratio	Standard Deviation 0.9312
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	3.8248 ratio	Standard Deviation 0.91875
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.9100 ratio	Standard Deviation 0.92453
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	4.0508 ratio	Standard Deviation 0.91154
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	3.8852 ratio	Standard Deviation 0.73498
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	3.8588 ratio	Standard Deviation 0.92894
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.7508 ratio	Standard Deviation 0.88092
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	3.9496 ratio	Standard Deviation 0.92977
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	3.9419 ratio	Standard Deviation 0.9867
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	3.9308 ratio	Standard Deviation 0.89274
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	3.7912 ratio	Standard Deviation 0.78337
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	3.9629 ratio	Standard Deviation 0.77435
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	3.9596 ratio	Standard Deviation 0.84943
Atorvastatin + PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	3.7436 ratio	Standard Deviation 0.86236
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	3.3986 ratio	Standard Deviation 0.7394
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	3.2359 ratio	Standard Deviation 0.65683
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	3.9132 ratio	Standard Deviation 0.79683
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.9841 ratio	Standard Deviation 0.8753
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.9205 ratio	Standard Deviation 0.79163
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	4.0036 ratio	Standard Deviation 0.99761
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.0223 ratio	Standard Deviation 0.81145
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	3.5668 ratio	Standard Deviation 0.77085
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	3.3510 ratio	Standard Deviation 0.79979
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	3.2700 ratio	Standard Deviation 0.68229
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	3.2550 ratio	Standard Deviation 0.66627
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	3.3318 ratio	Standard Deviation 0.70099
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	3.2882 ratio	Standard Deviation 0.68375
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	3.3259 ratio	Standard Deviation 0.70739
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	3.3277 ratio	Standard Deviation 0.71213
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	3.2632 ratio	Standard Deviation 0.60608
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	3.3855 ratio	Standard Deviation 0.6485
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	3.3073 ratio	Standard Deviation 0.81497
Atorvastatin + Ezetimibe 10 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	3.2832 ratio	Standard Deviation 0.72097
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	2.8436 ratio	Standard Deviation 0.67094
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	3.4940 ratio	Standard Deviation 1.02033
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	4.5057 ratio	Standard Deviation 1.18175
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	2.9176 ratio	Standard Deviation 0.75101
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	3.0528 ratio	Standard Deviation 0.77095
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	3.1204 ratio	Standard Deviation 0.72628
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	4.4256 ratio	Standard Deviation 1.20555
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	3.0676 ratio	Standard Deviation 0.92151
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	3.9264 ratio	Standard Deviation 1.11497
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	3.0044 ratio	Standard Deviation 0.77172
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	3.0868 ratio	Standard Deviation 0.75654
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.5408 ratio	Standard Deviation 1.11809
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	3.0760 ratio	Standard Deviation 0.78321
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	2.8300 ratio	Standard Deviation 0.81738
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	3.6024 ratio	Standard Deviation 1.07004
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	3.9896 ratio	Standard Deviation 0.99046
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	3.0260 ratio	Standard Deviation 0.7751
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	4.4975 ratio	Standard Deviation 1.25117
PF-04950615 50 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	2.8452 ratio	Standard Deviation 0.78785
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	4.2000 ratio	Standard Deviation 1.23292
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	2.3000 ratio	Standard Deviation 0.31095
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	2.9087 ratio	Standard Deviation 0.92317
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	2.2796 ratio	Standard Deviation 0.46691
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	2.5124 ratio	Standard Deviation 0.80082
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.8126 ratio	Standard Deviation 0.99748
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	2.5780 ratio	Standard Deviation 0.75738
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	2.4075 ratio	Standard Deviation 0.70042
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	2.2883 ratio	Standard Deviation 0.38697
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	2.3258 ratio	Standard Deviation 0.34951
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	2.4338 ratio	Standard Deviation 0.43218
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	3.1367 ratio	Standard Deviation 0.80233
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.2558 ratio	Standard Deviation 1.15512
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	2.5708 ratio	Standard Deviation 1.24941
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.6070 ratio	Standard Deviation 1.06034
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	2.7772 ratio	Standard Deviation 0.71059
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	3.5036 ratio	Standard Deviation 0.7625
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	2.2517 ratio	Standard Deviation 0.37291
PF-04950615 100 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	2.3639 ratio	Standard Deviation 0.45213
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	2.2121 ratio	Standard Deviation 0.37358
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	2.2800 ratio	Standard Deviation 0.3724
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	3.0941 ratio	Standard Deviation 0.80907
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	2.2335 ratio	Standard Deviation 0.42128
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	2.2529 ratio	Standard Deviation 0.39114
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	3.4029 ratio	Standard Deviation 0.86267
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	2.3004 ratio	Standard Deviation 0.42044
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.2610 ratio	Standard Deviation 1.08481
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	2.2658 ratio	Standard Deviation 0.43915
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	3.8970 ratio	Standard Deviation 1.4023
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	2.1896 ratio	Standard Deviation 0.37808
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	2.2225 ratio	Standard Deviation 0.37721
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	3.6450 ratio	Standard Deviation 1.45582
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	2.1988 ratio	Standard Deviation 0.36789
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	3.3500 ratio	Standard Deviation 1.37776
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	2.2142 ratio	Standard Deviation 0.37394
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	2.8208 ratio	Standard Deviation 1.08222
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	2.3617 ratio	Standard Deviation 0.35946
PF-04950615 150 mg	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	2.6050 ratio	Standard Deviation 0.53948
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 15	4.3017 ratio	Standard Deviation 0.84316
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 85	4.2613 ratio	Standard Deviation 1.08945
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 127	4.4717 ratio	Standard Deviation 1.06069
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 29	4.1023 ratio	Standard Deviation 0.8189
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 57	4.3361 ratio	Standard Deviation 0.97295
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 169	4.1182 ratio	Standard Deviation 0.81436
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 50	4.2909 ratio	Standard Deviation 0.97014
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Baseline	4.1076 ratio	Standard Deviation 0.88524
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 43	4.4074 ratio	Standard Deviation 1.03394
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 113	4.3570 ratio	Standard Deviation 0.88681
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 99	4.4200 ratio	Standard Deviation 1.15874
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 5	4.3259 ratio	Standard Deviation 0.99932
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 36	4.2222 ratio	Standard Deviation 0.97022
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 8	4.3374 ratio	Standard Deviation 0.88617
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 22	4.2822 ratio	Standard Deviation 0.97569
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 141	4.2843 ratio	Standard Deviation 1.17378
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 106	4.3157 ratio	Standard Deviation 1.01377
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 71	4.3791 ratio	Standard Deviation 1.1518
PF-04950615 Placebo	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio	Day 155	4.1804 ratio	Standard Deviation 1.03516

Secondary

Triglyceride (TG)

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 57	94.40 mg/dL	Standard Deviation 49.048
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 155	115.44 mg/dL	Standard Deviation 39.459
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Baseline	121.04 mg/dL	Standard Deviation 56.152
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 15	109.52 mg/dL	Standard Deviation 65.672
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 8	126.44 mg/dL	Standard Deviation 123.041
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 85	92.36 mg/dL	Standard Deviation 47.872
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 141	115.13 mg/dL	Standard Deviation 51.964
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 43	108.16 mg/dL	Standard Deviation 56.609
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 99	110.56 mg/dL	Standard Deviation 57.944
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 50	108.12 mg/dL	Standard Deviation 65.442
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 169	120.76 mg/dL	Standard Deviation 56.962
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 106	97.80 mg/dL	Standard Deviation 46.662
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 29	97.84 mg/dL	Standard Deviation 49.164
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 5	134.20 mg/dL	Standard Deviation 78.692
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 36	113.68 mg/dL	Standard Deviation 71.769
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 71	103.13 mg/dL	Standard Deviation 51.243
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 113	101.58 mg/dL	Standard Deviation 51.13
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 22	105.56 mg/dL	Standard Deviation 45.283
Atorvastatin + PF-04950615 50 mg	Triglyceride (TG)	Day 127	133.40 mg/dL	Standard Deviation 71.046
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 169	151.63 mg/dL	Standard Deviation 59.252
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 71	125.50 mg/dL	Standard Deviation 74.428
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 57	124.25 mg/dL	Standard Deviation 69.357
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 36	111.25 mg/dL	Standard Deviation 45.529
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 5	130.30 mg/dL	Standard Deviation 58.718
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 155	164.13 mg/dL	Standard Deviation 102.919
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 8	124.58 mg/dL	Standard Deviation 49.786
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 141	164.79 mg/dL	Standard Deviation 129.257
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 15	143.96 mg/dL	Standard Deviation 70.871
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 127	159.25 mg/dL	Standard Deviation 101.582
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 22	119.17 mg/dL	Standard Deviation 55.8
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Baseline	158.21 mg/dL	Standard Deviation 71.477
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 113	112.88 mg/dL	Standard Deviation 60.824
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 29	133.38 mg/dL	Standard Deviation 74.37
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 106	116.29 mg/dL	Standard Deviation 50.48
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 99	128.25 mg/dL	Standard Deviation 70.84
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 43	161.75 mg/dL	Standard Deviation 134.409
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 85	130.25 mg/dL	Standard Deviation 78.8
Atorvastatin + PF-04950615 100 mg	Triglyceride (TG)	Day 50	126.58 mg/dL	Standard Deviation 56.883
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 85	95.00 mg/dL	Standard Deviation 54.102
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 5	112.17 mg/dL	Standard Deviation 47.884
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 22	101.96 mg/dL	Standard Deviation 54.725
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 99	131.32 mg/dL	Standard Deviation 118.34
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 106	102.59 mg/dL	Standard Deviation 50.88
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 155	113.83 mg/dL	Standard Deviation 43.209
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 57	92.52 mg/dL	Standard Deviation 45.106
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 50	100.57 mg/dL	Standard Deviation 52.553
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 169	122.43 mg/dL	Standard Deviation 65.091
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 29	100.04 mg/dL	Standard Deviation 39.343
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 8	95.71 mg/dL	Standard Deviation 42.796
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 113	94.39 mg/dL	Standard Deviation 34.093
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 127	115.96 mg/dL	Standard Deviation 63.954
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 141	123.39 mg/dL	Standard Deviation 35.15
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 43	130.71 mg/dL	Standard Deviation 124.38
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 15	123.96 mg/dL	Standard Deviation 108.066
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Baseline	127.65 mg/dL	Standard Deviation 59.878
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 71	93.91 mg/dL	Standard Deviation 39.34
Atorvastatin + PF-04950615 150 mg	Triglyceride (TG)	Day 36	96.52 mg/dL	Standard Deviation 56.535
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 43	159.19 mg/dL	Standard Deviation 85.27
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 113	141.64 mg/dL	Standard Deviation 96.032
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 5	154.27 mg/dL	Standard Deviation 74.707
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 22	133.65 mg/dL	Standard Deviation 48.535
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 85	142.81 mg/dL	Standard Deviation 57.891
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 106	131.68 mg/dL	Standard Deviation 55.816
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 29	147.92 mg/dL	Standard Deviation 68.536
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 155	139.44 mg/dL	Standard Deviation 65.901
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 36	154.65 mg/dL	Standard Deviation 59.929
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Baseline	140.23 mg/dL	Standard Deviation 51.283
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 99	156.84 mg/dL	Standard Deviation 70.931
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 71	156.27 mg/dL	Standard Deviation 65.687
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 57	139.50 mg/dL	Standard Deviation 56.099
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 8	150.40 mg/dL	Standard Deviation 76.908
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 50	148.50 mg/dL	Standard Deviation 77.558
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 127	133.40 mg/dL	Standard Deviation 66.304
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 15	149.31 mg/dL	Standard Deviation 64.392
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 141	131.08 mg/dL	Standard Deviation 56.266
Atorvastatin + PF-04950615 Placebo	Triglyceride (TG)	Day 169	149.40 mg/dL	Standard Deviation 58.176
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 57	137.55 mg/dL	Standard Deviation 53.502
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Baseline	152.59 mg/dL	Standard Deviation 50.105
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 5	146.41 mg/dL	Standard Deviation 76.274
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 8	128.43 mg/dL	Standard Deviation 50.155
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 15	145.91 mg/dL	Standard Deviation 79.42
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 22	144.64 mg/dL	Standard Deviation 68.531
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 29	130.00 mg/dL	Standard Deviation 52.743
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 36	139.95 mg/dL	Standard Deviation 79.796
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 43	135.23 mg/dL	Standard Deviation 70.762
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 50	121.64 mg/dL	Standard Deviation 51.406
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 71	139.27 mg/dL	Standard Deviation 85.017
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 85	142.45 mg/dL	Standard Deviation 60.126
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 99	137.82 mg/dL	Standard Deviation 60.866
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 106	133.41 mg/dL	Standard Deviation 68.902
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 113	129.14 mg/dL	Standard Deviation 73.031
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 127	153.14 mg/dL	Standard Deviation 62.304
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 141	156.27 mg/dL	Standard Deviation 76.965
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 155	149.23 mg/dL	Standard Deviation 68.51
Atorvastatin + Ezetimibe 10 mg	Triglyceride (TG)	Day 169	167.91 mg/dL	Standard Deviation 79.436
PF-04950615 50 mg	Triglyceride (TG)	Day 71	122.68 mg/dL	Standard Deviation 52.192
PF-04950615 50 mg	Triglyceride (TG)	Day 8	122.72 mg/dL	Standard Deviation 66.459
PF-04950615 50 mg	Triglyceride (TG)	Day 15	125.64 mg/dL	Standard Deviation 55.667
PF-04950615 50 mg	Triglyceride (TG)	Day 169	126.67 mg/dL	Standard Deviation 60.29
PF-04950615 50 mg	Triglyceride (TG)	Day 29	111.24 mg/dL	Standard Deviation 46.683
PF-04950615 50 mg	Triglyceride (TG)	Day 155	129.00 mg/dL	Standard Deviation 70.01
PF-04950615 50 mg	Triglyceride (TG)	Day 127	138.08 mg/dL	Standard Deviation 60.533
PF-04950615 50 mg	Triglyceride (TG)	Day 43	123.80 mg/dL	Standard Deviation 52.925
PF-04950615 50 mg	Triglyceride (TG)	Day 106	116.16 mg/dL	Standard Deviation 55.618
PF-04950615 50 mg	Triglyceride (TG)	Day 50	123.48 mg/dL	Standard Deviation 61.199
PF-04950615 50 mg	Triglyceride (TG)	Baseline	122.40 mg/dL	Standard Deviation 50.578
PF-04950615 50 mg	Triglyceride (TG)	Day 5	128.20 mg/dL	Standard Deviation 79.256
PF-04950615 50 mg	Triglyceride (TG)	Day 141	135.80 mg/dL	Standard Deviation 75.159
PF-04950615 50 mg	Triglyceride (TG)	Day 22	125.00 mg/dL	Standard Deviation 54.636
PF-04950615 50 mg	Triglyceride (TG)	Day 36	115.12 mg/dL	Standard Deviation 54.424
PF-04950615 50 mg	Triglyceride (TG)	Day 85	118.64 mg/dL	Standard Deviation 46.593
PF-04950615 50 mg	Triglyceride (TG)	Day 57	102.28 mg/dL	Standard Deviation 33.512
PF-04950615 50 mg	Triglyceride (TG)	Day 113	111.72 mg/dL	Standard Deviation 53.875
PF-04950615 50 mg	Triglyceride (TG)	Day 99	122.96 mg/dL	Standard Deviation 55.697
PF-04950615 100 mg	Triglyceride (TG)	Day 113	116.26 mg/dL	Standard Deviation 69.771
PF-04950615 100 mg	Triglyceride (TG)	Day 15	113.52 mg/dL	Standard Deviation 60.601
PF-04950615 100 mg	Triglyceride (TG)	Day 169	166.22 mg/dL	Standard Deviation 176.973
PF-04950615 100 mg	Triglyceride (TG)	Baseline	124.40 mg/dL	Standard Deviation 59.717
PF-04950615 100 mg	Triglyceride (TG)	Day 127	139.83 mg/dL	Standard Deviation 103.182
PF-04950615 100 mg	Triglyceride (TG)	Day 8	103.50 mg/dL	Standard Deviation 48.515
PF-04950615 100 mg	Triglyceride (TG)	Day 50	114.22 mg/dL	Standard Deviation 53.09
PF-04950615 100 mg	Triglyceride (TG)	Day 57	117.21 mg/dL	Standard Deviation 84.666
PF-04950615 100 mg	Triglyceride (TG)	Day 36	109.17 mg/dL	Standard Deviation 54.052
PF-04950615 100 mg	Triglyceride (TG)	Day 99	118.17 mg/dL	Standard Deviation 63.727
PF-04950615 100 mg	Triglyceride (TG)	Day 71	112.13 mg/dL	Standard Deviation 56.034
PF-04950615 100 mg	Triglyceride (TG)	Day 155	119.91 mg/dL	Standard Deviation 61.088
PF-04950615 100 mg	Triglyceride (TG)	Day 29	142.84 mg/dL	Standard Deviation 141.763
PF-04950615 100 mg	Triglyceride (TG)	Day 43	119.44 mg/dL	Standard Deviation 53.11
PF-04950615 100 mg	Triglyceride (TG)	Day 106	109.91 mg/dL	Standard Deviation 45.304
PF-04950615 100 mg	Triglyceride (TG)	Day 22	109.04 mg/dL	Standard Deviation 49.088
PF-04950615 100 mg	Triglyceride (TG)	Day 5	115.40 mg/dL	Standard Deviation 52.401
PF-04950615 100 mg	Triglyceride (TG)	Day 141	119.91 mg/dL	Standard Deviation 59.343
PF-04950615 100 mg	Triglyceride (TG)	Day 85	100.04 mg/dL	Standard Deviation 53.185
PF-04950615 150 mg	Triglyceride (TG)	Day 127	124.50 mg/dL	Standard Deviation 86.402
PF-04950615 150 mg	Triglyceride (TG)	Day 71	103.13 mg/dL	Standard Deviation 47.534
PF-04950615 150 mg	Triglyceride (TG)	Day 43	109.29 mg/dL	Standard Deviation 54.365
PF-04950615 150 mg	Triglyceride (TG)	Day 85	99.92 mg/dL	Standard Deviation 40.798
PF-04950615 150 mg	Triglyceride (TG)	Day 36	105.67 mg/dL	Standard Deviation 38.421
PF-04950615 150 mg	Triglyceride (TG)	Day 99	115.08 mg/dL	Standard Deviation 63.629
PF-04950615 150 mg	Triglyceride (TG)	Day 22	113.79 mg/dL	Standard Deviation 106.198
PF-04950615 150 mg	Triglyceride (TG)	Day 29	94.29 mg/dL	Standard Deviation 37.698
PF-04950615 150 mg	Triglyceride (TG)	Day 106	93.54 mg/dL	Standard Deviation 38.52
PF-04950615 150 mg	Triglyceride (TG)	Day 15	114.25 mg/dL	Standard Deviation 54.003
PF-04950615 150 mg	Triglyceride (TG)	Day 113	101.43 mg/dL	Standard Deviation 52.274
PF-04950615 150 mg	Triglyceride (TG)	Day 8	130.91 mg/dL	Standard Deviation 75.156
PF-04950615 150 mg	Triglyceride (TG)	Day 5	114.25 mg/dL	Standard Deviation 61.969
PF-04950615 150 mg	Triglyceride (TG)	Day 141	129.13 mg/dL	Standard Deviation 70.19
PF-04950615 150 mg	Triglyceride (TG)	Baseline	111.58 mg/dL	Standard Deviation 42.354
PF-04950615 150 mg	Triglyceride (TG)	Day 169	128.26 mg/dL	Standard Deviation 71.26
PF-04950615 150 mg	Triglyceride (TG)	Day 155	133.33 mg/dL	Standard Deviation 81.1
PF-04950615 150 mg	Triglyceride (TG)	Day 57	90.67 mg/dL	Standard Deviation 28.925
PF-04950615 150 mg	Triglyceride (TG)	Day 50	113.29 mg/dL	Standard Deviation 53.87
PF-04950615 Placebo	Triglyceride (TG)	Day 141	137.35 mg/dL	Standard Deviation 56.775
PF-04950615 Placebo	Triglyceride (TG)	Day 15	130.65 mg/dL	Standard Deviation 53.724
PF-04950615 Placebo	Triglyceride (TG)	Day 106	139.00 mg/dL	Standard Deviation 53.142
PF-04950615 Placebo	Triglyceride (TG)	Baseline	130.39 mg/dL	Standard Deviation 49.826
PF-04950615 Placebo	Triglyceride (TG)	Day 50	142.30 mg/dL	Standard Deviation 83.014
PF-04950615 Placebo	Triglyceride (TG)	Day 71	146.43 mg/dL	Standard Deviation 64.368
PF-04950615 Placebo	Triglyceride (TG)	Day 22	130.26 mg/dL	Standard Deviation 59.246
PF-04950615 Placebo	Triglyceride (TG)	Day 99	133.91 mg/dL	Standard Deviation 49.879
PF-04950615 Placebo	Triglyceride (TG)	Day 85	119.17 mg/dL	Standard Deviation 57.046
PF-04950615 Placebo	Triglyceride (TG)	Day 155	131.74 mg/dL	Standard Deviation 62.736
PF-04950615 Placebo	Triglyceride (TG)	Day 29	122.09 mg/dL	Standard Deviation 49.749
PF-04950615 Placebo	Triglyceride (TG)	Day 36	158.30 mg/dL	Standard Deviation 102.642
PF-04950615 Placebo	Triglyceride (TG)	Day 127	159.43 mg/dL	Standard Deviation 89.13
PF-04950615 Placebo	Triglyceride (TG)	Day 5	121.09 mg/dL	Standard Deviation 48.602
PF-04950615 Placebo	Triglyceride (TG)	Day 43	140.61 mg/dL	Standard Deviation 73.706
PF-04950615 Placebo	Triglyceride (TG)	Day 8	136.91 mg/dL	Standard Deviation 91.378
PF-04950615 Placebo	Triglyceride (TG)	Day 113	136.61 mg/dL	Standard Deviation 64.291
PF-04950615 Placebo	Triglyceride (TG)	Day 169	125.41 mg/dL	Standard Deviation 36.439
PF-04950615 Placebo	Triglyceride (TG)	Day 57	136.78 mg/dL	Standard Deviation 67.987

Secondary

Very Low Density Lipoprotein-Cholesterol (VLDL-C)

Time frame: Baseline, Day 5, 8, 15, 22, 29, 36, 43, 50, 57, 71, 85, 99, 106, 113, 127, 141, 155, 169

Arm	Measure	Group	Value (MEAN)	Dispersion
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	16.56 mg/dL	Standard Deviation 6.246
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	15.92 mg/dL	Standard Deviation 7.064
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	19.92 mg/dL	Standard Deviation 9.312
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	16.20 mg/dL	Standard Deviation 6.371
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	21.36 mg/dL	Standard Deviation 9.999
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	16.36 mg/dL	Standard Deviation 9.269
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	18.88 mg/dL	Standard Deviation 7.732
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	17.04 mg/dL	Standard Deviation 6.761
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	17.00 mg/dL	Standard Deviation 3.905
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	15.76 mg/dL	Standard Deviation 7.253
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	14.24 mg/dL	Standard Deviation 6.247
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	15.83 mg/dL	Standard Deviation 8.726
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	14.36 mg/dL	Standard Deviation 6.034
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	18.13 mg/dL	Standard Deviation 7.279
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	18.96 mg/dL	Standard Deviation 9.361
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	20.48 mg/dL	Standard Deviation 11.594
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	14.44 mg/dL	Standard Deviation 6.545
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	19.64 mg/dL	Standard Deviation 13.073
Atorvastatin + PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	17.20 mg/dL	Standard Deviation 8.921
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	15.96 mg/dL	Standard Deviation 6.328
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	18.04 mg/dL	Standard Deviation 10.378
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	22.25 mg/dL	Standard Deviation 15.109
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	19.70 mg/dL	Standard Deviation 8.249
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	17.67 mg/dL	Standard Deviation 6.787
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	16.54 mg/dL	Standard Deviation 7.863
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	20.42 mg/dL	Standard Deviation 9.93
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	23.79 mg/dL	Standard Deviation 11.286
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	17.63 mg/dL	Standard Deviation 8.816
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	21.42 mg/dL	Standard Deviation 7.442
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	19.04 mg/dL	Standard Deviation 7.41
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	18.00 mg/dL	Standard Deviation 6.574
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	19.88 mg/dL	Standard Deviation 9.967
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	17.50 mg/dL	Standard Deviation 9.212
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	15.33 mg/dL	Standard Deviation 4.984
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	23.21 mg/dL	Standard Deviation 14.231
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	17.46 mg/dL	Standard Deviation 8.939
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	22.21 mg/dL	Standard Deviation 11.858
Atorvastatin + PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	21.33 mg/dL	Standard Deviation 13.77
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	14.04 mg/dL	Standard Deviation 6.745
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	18.04 mg/dL	Standard Deviation 10.813
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	16.50 mg/dL	Standard Deviation 9.869
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	17.30 mg/dL	Standard Deviation 6.292
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	17.22 mg/dL	Standard Deviation 5.977
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	16.52 mg/dL	Standard Deviation 7.141
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	15.58 mg/dL	Standard Deviation 6.192
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	15.26 mg/dL	Standard Deviation 5.056
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	14.04 mg/dL	Standard Deviation 5.842
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	14.39 mg/dL	Standard Deviation 6.966
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	13.87 mg/dL	Standard Deviation 4.674
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	14.59 mg/dL	Standard Deviation 5.981
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	16.61 mg/dL	Standard Deviation 7.686
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	18.68 mg/dL	Standard Deviation 17.7
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	20.92 mg/dL	Standard Deviation 7.651
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	13.83 mg/dL	Standard Deviation 3.95
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	14.65 mg/dL	Standard Deviation 6.786
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	17.39 mg/dL	Standard Deviation 5.007
Atorvastatin + PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	15.39 mg/dL	Standard Deviation 4.717
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	21.72 mg/dL	Standard Deviation 10.577
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	19.32 mg/dL	Standard Deviation 7.33
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	21.88 mg/dL	Standard Deviation 14.701
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	19.60 mg/dL	Standard Deviation 7.286
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	23.04 mg/dL	Standard Deviation 9.035
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	21.65 mg/dL	Standard Deviation 7.573
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	23.85 mg/dL	Standard Deviation 10.657
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	21.88 mg/dL	Standard Deviation 9.523
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	20.56 mg/dL	Standard Deviation 9.319
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	21.92 mg/dL	Standard Deviation 9.587
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	21.42 mg/dL	Standard Deviation 6.858
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	19.16 mg/dL	Standard Deviation 9.573
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	23.65 mg/dL	Standard Deviation 12.547
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	21.69 mg/dL	Standard Deviation 11.235
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	20.88 mg/dL	Standard Deviation 7.957
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	21.77 mg/dL	Standard Deviation 9.868
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	19.32 mg/dL	Standard Deviation 9.534
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	22.58 mg/dL	Standard Deviation 7.991
Atorvastatin + PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	21.72 mg/dL	Standard Deviation 11.085
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	19.23 mg/dL	Standard Deviation 6.718
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	24.55 mg/dL	Standard Deviation 11.931
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	22.48 mg/dL	Standard Deviation 7.869
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	21.59 mg/dL	Standard Deviation 9.169
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	18.50 mg/dL	Standard Deviation 7.951
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	21.55 mg/dL	Standard Deviation 5.878
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	21.95 mg/dL	Standard Deviation 8.249
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	21.59 mg/dL	Standard Deviation 7.992
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	22.73 mg/dL	Standard Deviation 10.552
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	21.41 mg/dL	Standard Deviation 7.028
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	20.82 mg/dL	Standard Deviation 8.151
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	21.59 mg/dL	Standard Deviation 7.866
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	22.68 mg/dL	Standard Deviation 9.712
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	20.14 mg/dL	Standard Deviation 7.298
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	19.77 mg/dL	Standard Deviation 5.936
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	20.29 mg/dL	Standard Deviation 7.1
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	20.95 mg/dL	Standard Deviation 7.712
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	23.68 mg/dL	Standard Deviation 9.564
Atorvastatin + Ezetimibe 10 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	18.64 mg/dL	Standard Deviation 6.499
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	19.04 mg/dL	Standard Deviation 6.846
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	17.48 mg/dL	Standard Deviation 8.186
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	19.30 mg/dL	Standard Deviation 9.632
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	17.44 mg/dL	Standard Deviation 7.509
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	17.84 mg/dL	Standard Deviation 6.756
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	19.80 mg/dL	Standard Deviation 11.927
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	17.28 mg/dL	Standard Deviation 6.901
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	17.20 mg/dL	Standard Deviation 7.984
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	19.13 mg/dL	Standard Deviation 8.644
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	18.52 mg/dL	Standard Deviation 9.265
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	15.44 mg/dL	Standard Deviation 5.108
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	17.76 mg/dL	Standard Deviation 7.573
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	19.72 mg/dL	Standard Deviation 8.091
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	20.00 mg/dL	Standard Deviation 7.708
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	17.00 mg/dL	Standard Deviation 7.746
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	19.52 mg/dL	Standard Deviation 10.627
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	16.68 mg/dL	Standard Deviation 7.04
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	15.92 mg/dL	Standard Deviation 8.246
PF-04950615 50 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	18.64 mg/dL	Standard Deviation 9.995
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	16.28 mg/dL	Standard Deviation 8.735
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	16.08 mg/dL	Standard Deviation 8.356
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	16.25 mg/dL	Standard Deviation 6.661
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	16.42 mg/dL	Standard Deviation 6.58
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	19.68 mg/dL	Standard Deviation 16.106
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	16.46 mg/dL	Standard Deviation 6.129
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	17.66 mg/dL	Standard Deviation 9.09
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	18.12 mg/dL	Standard Deviation 7.316
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	17.04 mg/dL	Standard Deviation 7.151
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	16.83 mg/dL	Standard Deviation 12.437
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	16.79 mg/dL	Standard Deviation 6.84
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	14.09 mg/dL	Standard Deviation 6.735
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	16.46 mg/dL	Standard Deviation 9.514
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	16.09 mg/dL	Standard Deviation 5.672
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	15.96 mg/dL	Standard Deviation 8.466
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	17.91 mg/dL	Standard Deviation 11.445
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	17.61 mg/dL	Standard Deviation 7.518
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	16.17 mg/dL	Standard Deviation 8.144
PF-04950615 100 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	23.00 mg/dL	Standard Deviation 23.279
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	14.63 mg/dL	Standard Deviation 6.337
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	14.04 mg/dL	Standard Deviation 4.639
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	15.50 mg/dL	Standard Deviation 5.905
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	15.54 mg/dL	Standard Deviation 7.818
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	13.04 mg/dL	Standard Deviation 6.753
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	13.54 mg/dL	Standard Deviation 4.222
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	17.17 mg/dL	Standard Deviation 14.199
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	18.00 mg/dL	Standard Deviation 10.167
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	18.92 mg/dL	Standard Deviation 10.738
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	16.96 mg/dL	Standard Deviation 6.734
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	18.00 mg/dL	Standard Deviation 10.065
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	16.25 mg/dL	Standard Deviation 10.605
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	16.63 mg/dL	Standard Deviation 6.273
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	18.95 mg/dL	Standard Deviation 9.81
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	17.38 mg/dL	Standard Deviation 12.631
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	13.13 mg/dL	Standard Deviation 5.788
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	18.54 mg/dL	Standard Deviation 9.913
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	16.21 mg/dL	Standard Deviation 8.49
PF-04950615 150 mg	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	13.87 mg/dL	Standard Deviation 6.107
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 5	20.68 mg/dL	Standard Deviation 10.035
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 113	19.39 mg/dL	Standard Deviation 8.322
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 85	16.43 mg/dL	Standard Deviation 8.877
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 71	22.61 mg/dL	Standard Deviation 9.014
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 57	20.13 mg/dL	Standard Deviation 10.092
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 127	21.61 mg/dL	Standard Deviation 13.121
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 50	22.26 mg/dL	Standard Deviation 13.685
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 43	22.78 mg/dL	Standard Deviation 11.631
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Baseline	17.50 mg/dL	Standard Deviation 8.549
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 169	19.68 mg/dL	Standard Deviation 8.306
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 141	20.09 mg/dL	Standard Deviation 9.409
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 36	24.22 mg/dL	Standard Deviation 17.231
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 29	19.00 mg/dL	Standard Deviation 8.258
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 22	18.13 mg/dL	Standard Deviation 9.416
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 155	18.57 mg/dL	Standard Deviation 9.11
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 15	20.43 mg/dL	Standard Deviation 10.612
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 8	22.48 mg/dL	Standard Deviation 13.737
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 106	20.00 mg/dL	Standard Deviation 9.376
PF-04950615 Placebo	Very Low Density Lipoprotein-Cholesterol (VLDL-C)	Day 99	21.13 mg/dL	Standard Deviation 8.981

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113

Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85

Apolipoprotein A-I (ApoA-I)

Apolipoprotein A-II (ApoA-II)

Apolipoprotein B (ApoB)

Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615

Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113

Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113

Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113

Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113

Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113

Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113

Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113

Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113

Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113

Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113

Change From Baseline in Triglyceride (TG) at Day 85 and Day 113

Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113

High Density Lipoprotein- Cholesterol (HDL-C)

Lipoprotein (a) (Lp[a])

Low Density Lipoprotein-Cholesterol (LDL-C)

Maximum Observed Plasma Concentration (Cmax) of PF-04950615

Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615

Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)

Number of Participants With Anti-Drug Antibody (ADA) Response

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)

Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter

Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113

Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113

Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113

Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113

Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113

Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113

Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113

Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113

Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113

Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113

Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113

Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

Terminal Elimination Half-Life (t1/2) of PF-04950615

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615

Total Cholesterol (TC)

Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio

Triglyceride (TG)

Very Low Density Lipoprotein-Cholesterol (VLDL-C)